ELSEVIER

International Journal of Pharmaceutics 211 (2000) 97–118

international journal of pharmaceutics

www.elsevier.com/locate/ijpharm

Author index Volumes 193–211 (2000)

A. Basford, P., see D. Ticehurst, M. **193**, 247
Aberturas, M.R., see Molpeceres, J. **197**, 129
Abou El Hassan, M.A.I., D.J. Touw, A.J. Wilhelm, A. Bast, W.J.F. van der Vijgh, Stability of monoHER in an aqueous formulation for i.v. administration **211**, 51
Aceves, J.M., R. Cruz, E. Hernandez, Preparation and characterization of Furosemide-Eudragit controlled release systems **195**, 45
Adami, R.C., see Kwok, K.Y. **203**, 81
Adeyeye, C.M., see Ebube, N.K. **196**, 27
Agarwal, V., see Khan, M.A. **193**, 147
Agatonovic-Kustrin, S., see Alany, R.G. **196**, 141
Agnew, B.J., see Patel, G.B. **194**, 39
Agu, R.U., see Ugwoke, M.I. **205**, 43
Ahlin, P., J. Kristl, M. Šentjurc, J. Štrancar, S. Pečar, Influence of spin probe structure on its distribution in SLN dispersions **196**, 241
Ahmad, I., see Perkins, W.R. **200**, 27
Ahola, M., P. Kortesuo, I. Kangasniemi, J. Kiesvaara, A. Yli-Urpo, Silica xerogel carrier material for controlled release of toremifene citrate **195**, 219
Ahola, M., see Kortesuo, P. **200**, 223
Ahuja, N., see Singh, B. **195**, 247
Alany, R.G., T. Rades, S. Agatonovic-Kustrin, N.M. Davies, I.G. Tucker, Effects of alcohols and diols on the phase behaviour of quaternary systems **196**, 141
Albarghouthi, M., D.A. Fara, M. Saleem, T. El-Thaher, K. Matalka, A. Badwan, Immobilization of antibodies on alginate-chitosan beads **206**, 23
Albina, E., see Torché, A.-M. **201**, 15
Ali-Abi, Z., see Bentley, M.V.L.B. **193**, 49
Ali, F.M., see Monem, A.S. **198**, 29
Ali, S., see Perkins, W.R. **200**, 27
Allender, C.J., C. Richardson, B. Woodhouse, C.M. Heard, K.R. Brain, Pharmaceutical applications for molecularly imprinted polymers **195**, 39
Alvarez-Lorenzo, C., J.L. Gómez-Amoza, R. Martínez-Pacheco, C. Souto, A. Concheiro, Evaluation of low-substituted hydroxypropylcelluloses (L-HPCs) as filler-binders for direct compression **197**, 107
Alvarez-Lorenzo, C., see Gutiérrez de Rubalcava, C. **203**, 99
Alvarez-Núñez, F.A., S.H. Yalkowsky, Relationship between Polysorbate 80 solubilization descriptors and octanol–water partition coefficients of drugs **200**, 217
Alwan, A., see Birchall, J.C. **197**, 233
Aly, H.M., see Amin, A.S. **205**, 35
Amaral, J., see Bettencourt, A. **197**, 161
Amighi, K., see Semdé, R. **197**, 181
Amighi, K., see Semdé, R. **197**, 169
Amin, A.S., H.M. Aly, Utilization of colorimetric and atomic absorption spectrometric determination of aztreonam through ion pair complex formation **205**, 35
Andry, M.-C., see Pariot, N. **211**, 19
Anigbogu, A., S. Patil, P. Singh, P. Liu, S. Dinh, H. Maibach, An in vivo investigation of the rabbit skin responses to transdermal iontophoresis **200**, 195
Antikainen, O., see Krogars, K. **199**, 187
Arenare, L., see Bonina, F.P. **202**, 79
Arnaud, P., see Skiba, M. **198**, 1
Arunothayanun, P., M.-S. Bernard, D.Q.M. Craig, I.F. Uchegbu, A.T. Florence, The effect of processing variables on the physical characteristics of non-ionic surfactant vesicles (niosomes) formed from a hexadecyl diglycerol ether **201**, 7
Asai, Y., S. Watanabe, Formation and stability of the dispersed particles composed of retinoic acid, sesame oil and phosphatidylcholine **193**, 189
Asakawa, K., see Hanawa, T. **210**, 109
Asbill, C.S., see El-Kattan, A.F. **198**, 179
Ashurst, I.C., see Michael, Y. **200**, 279
Attwood, D., *Pharmaceutical Emulsions and Suspensions*, Edited by, F. Nielloud and G. Marti-Meatres. ISBN 0-824-0304-9 **205**, 199
Attwood, D., see Milhem, O.M. **197**, 239
Attwood, D., see Miyazaki, S. **204**, 127
Audus, K.L., see Foster, K.A. **208**, 1
Audus, K.L., see Utoguchi, N. **195**, 115
Augustijns, P., see Uchenna Agu, R. **193**, 219
Augustijns, P., see Ugwoke, M.I. **205**, 43
Augustijns, P., see Van Gelder, J. **205**, 93
Avery, M.L., see Foster, K.A. **208**, 1
Ayora Cañada, M.J., M.I. Pascual Reguera, A. Molina Díaz, Selective determination of pyridoxine in the presence of hydrosoluble vitamins using a continuous-flow solid phase

PII: S0378-5173(00)00646-3

sensing device with UV detection **202**, 113

Badawy, S.I.F., M.M. Menning, M.A. Gorko, D.L. Gilbert, Effect of process parameters on compressibility of granulation manufactured in a high-shear mixer **198**, 51
Badwan, A., see Albarghouthi, M. **206**, 23
Bagster, D.F., see Chew, N.Y.K. **206**, 75
Baker, G.R., see Whitaker, M. **205**, 79
Baluom, M., M. Friedman, A. Rubinstein, Erratum to "The importance of intestinal residence time of absorption enhancer on drug absorption and implication on formulative considerations": [Int. J. Pharm. 176 (1998) 21–30] **193**, 265
Banga, A.K., see Chang, S.-L. **200**, 107
Bao, J., see Hu, Q. **202**, 121
Bárány, E., M. Lindberg, M. Lodén, Unexpected skin barrier influence from nonionic emulsifiers **195**, 189
Baras, B., M.-A. Benoit, J. Gillard, Parameters influencing the antigen release from spray-dried poly(DL-lactide) microparticles **200**, 133
Barbuzzi, T., see Saija, A. **199**, 39
Bárdos-Nagy, I., see Galántai, R. **195**, 207
Barker, S.A., see Wissing, S. **199**, 141
Barnett, P., see Patel, D. **200**, 271
Barra, J., see Bustamante, P. **194**, 117
Barrales-Rienda, J.M., see Frutos Cabanillas, P. **209**, 15
Barry, B.W., see El Maghraby, G.M.M. **204**, 159
Barry, B.W., see El Maghraby, G.M.M. **196**, 63
Barthélémy, C., see Di Martino, P. **197**, 95
Baruffini, A., see Perugini, P. **196**, 51
Barzegar-Jalali, M., see Dastmalchi, S. **202**, 41
Başcı, N.E., see Öztürk, F. **204**, 97
Başcı, N.E., see Öztürk, F. **204**, 91
Bast, A., see Abou El Hassan, M.A.I. **211**, 51
Bataille, B., see Billon, A. **203**, 159
Battaglia, G., see Bonina, F.P. **202**, 79
Baumgartner, S., J. Kristl, F. Vrečer, P. Vodopivec, B. Zorko, Optimisation of floating matrix tablets and evaluation of their gastric residence time **195**, 125
Baykara, T., see Yuksel, N. **209**, 57
Bechgaard, E., see Lindhardt, K. **205**, 159
Bechgaard, E., see Nielsen, H.W. **204**, 35
Bécourt, P., see Maillard-Salin, D.G. **200**, 121
Bécourt, P., see Maillard-Salin, D.G. **199**, 29
Beetge, E., J. du Plessis, D.G. Müller, C. Goosen, F.J. van Rensburg, The influence of the physicochemical characteristics and pharmacokinetic properties of selected NSAID's on their transdermal absorption **193**, 261
Beezer, A.E., Comments on Serger et al.'s, (1998, 1999) calorimetric stability studies **207**, 117
Behan-Martin, M.K., see Eccleston, G.M. **203**, 127
Beijnen, J.H., see Nuijen, B. **194**, 261
Beijnen, J.H., see van Maanen, M.J. **200**, 187
Beijnen, J.H., see van Maanen, R.J. **196**, 85
Belchamber, R.M., see Whitaker, M. **205**, 79
Bengtsson, T., see Borgström, L. **193**, 227
Benita, S., see Gershanik, T. **211**, 29
Benoit, M.-A., see Baras, B. **200**, 133
Bentley, M.V.L.B., J.M. Marchetti, N. Ricardo, Z. Ali-Abi, J.H. Collett, Influence of lecithin on some physical chemical properties of poloxamer gels: rheological, microscopic and in vitro permeation studies **193**, 49
Bentley, M.V.L.B., see Lopez, R.F.V. **200**, 127
Bergenståhl, B., see Welin-Berger, K. **200**, 249
Berges, L., see Molpeceres, J. **197**, 129
Bergström, K., see Karhu, M. **196**, 95
Berlo, J.A., see De Brabander, C. **208**, 81
Bernabei, M.T., see Bulgarelli, E. **198**, 157
Bernabei, M.T., see Leo, E. **196**, 1
Bernard, M.-S., see Arunothayanun, P. **201**, 7
Bernkop-Schnürch, A., Chitosan and its derivatives: potential excipients for peroral peptide delivery systems **194**, 1
Bernkop-Schnürch, A., S. Steininger, Synthesis and characterisation of mucoadhesive thiolated polymers **194**, 239
Beronius, P., see Karami, K. **201**, 121
Berridge, M.S., see Lee, Z. **199**, 7
Bettencourt, A., A. Calado, J. Amaral, F.M. Vale, J.M.T. Rico, J. Monteiro, A. Lopes, L. Pereira, M. Castro, In vitro release studies of methylmethacrylate liberation from acrylic cement powder **197**, 161
Bette, P., see Nuijen, B. **194**, 261
Bettinetti, G.P., see Bonferoni, M.C. **200**, 207
Bibby, D.C., N.M. Davies, I.G. Tucker, Mechanisms by which cyclodextrins modify drug release from polymeric drug delivery systems **197**, 1
Billa, N., K.-H. Yuen, M.A.A. Khader, A. Omar, Gamma-scintigraphic study of the gastrointestinal transit and in vivo dissolution of a controlled release diclofenac sodium formulation in xanthan gum matrices **201**, 109
Billon, A., B. Bataille, G. Cassanas, M. Jacob, Development of spray-dried acetaminophen microparticles using experimental designs **203**, 159
Bi, M., J. Singh, Effect of buffer pH, buffer concentration and skin with or without enzyme inhibitors on the stability of [Arg^8]-vasopressin **197**, 87
Binglin, H., see Tongwen, X. **197**, 23
Birchall, J.C., C. Marichal, L. Campbell, A. Alwan, J. Hadgraft, M. Gumbleton, Gene expression in an intact ex-vivo skin tissue model following percutaneous delivery of cationic liposome–plasmid DNA complexes **197**, 233
Birchall, J.C., I.W. Kellaway, M. Gumbleton, Physical stability and in-vitro gene expression efficiency of nebulised lipid–peptide–DNA complexes **197**, 221
Birchall, J., see Ramsay, E. **210**, 97
Bittner, B., see Mountfield, R.J. **211**, 89
Bittner, B., T. Thelly, H. Isel, R.J. Mountfield, The impact of co-solvents and the composition of experimental formulations on the pump rate of the ALZET® osmotic pump **205**, 195
Biziulevičius, G.A., V. Žukaitė, Fabrication of oral acid resistant Fermosorb (ferment + sorbent)-type preparations can be simplified using industrial *Bacillus subtilis* culture filtrates as an enzyme source **204**, 43

Bjerregaard, S., I. Söderberg, C. Vermehren, S. Frokjaer, Formulation and evaluation of release and swelling mechanism of a water-in-oil emulsion using factorial design **193**, 1
Björk, E., see Dahlin, M. **195**, 197
Blanco, M.D., C. Gómez, R. Olmo, E. Muñiz, J.M. Teijón, Chitosan microspheres in PLG films as devices for cytarabine release **202**, 29
Bloomfield, M.S., W.C. Butler, Robustness testing, using experimental design, of a flow-through dissolution method for a product where the actives have markedly differing solubility properties **206**, 55
Boatto, G., see Bonina, F.P. **202**, 79
Bocca, C., see Miglietta, A. **210**, 61
Bodmeier, R., see Siepmann, J. **201**, 151
Boelsma, E., see Ponec, M. **203**, 211
Bogaerts, P., see Some, I.T. **198**, 39
Bogardus, J.B., see Gandhi, R.B. **201**, 221
Boje, K.M.K., see Mahar Doan, K.M. **194**, 209
Bolhuis, G.K., see van Veen, B. **203**, 71
Boneschans, B., see Lovrek, M. **200**, 59
Bonferoni, M.C., S. Rossi, F. Ferrari, G.P. Bettinetti, C. Caramella, Characterization of a diltiazem-lambda carrageenan complex **200**, 207
Bonina, F.P., L. Arenare, R. Ippolito, G. Boatto, G. Battaglia, V. Bruno, P. de Caprariis, Synthesis, pharmacokinetics and anticonvulsant activity of 7-chlorokynurenic acid prodrugs **202**, 79
Bonina, F., see Saija, A. **199**, 39
Borchert, D., see Loth, H. **209**, 95
Borgström, L., T. Bengtsson, E. Derom, R. Pauwels, Variability in lung deposition of inhaled drug, within and between asthmatic patients, with a pMDI and a dry powder inhaler, Turbuhaler® **193**, 227
Bos, G.W., A. Trullas-Jimeno, W. Jiskoot, D.J.A. Crommelin, W.E. Hennink, Sterilization of poly(dimethylamino) ethyl methacrylate-based gene transfer complexes **211**, 79
Bouma, M., see Nuijen, B. **194**, 261
Bouwstra, J., see Ponec, M. **203**, 211
Bowman, B.J., see Kosasih, A. **204**, 81
Bozkurt, A., see Öztürk, F. **204**, 97
Bozkurt, A., see Öztürk, F. **204**, 91
Bragger, J.L., see Soozandehfar, S.H. **198**, 71
Brain, K.R., see Allender, C.J. **195**, 39
Bramanti, G., see Mura, P. **193**, 85
Brandl, M., see Moog, R. **206**, 43
Brauns, U., see Nuijen, B. **194**, 261
Bridges, P.A., K.M.G. Taylor, An investigation of some of the factors influencing the jet nebulisation of liposomes **204**, 69
Bridgwater, J., see Rough, S.L. **204**, 117
Brisaert, M., J. Plaizier-Vercammen, Investigation on the photostability of a tretinoin lotion and stabilization with additives **199**, 49
Brisaert, M., M. Gabriëls, J. Plaizier-Vercammen, Investigation of the chemical stability of an erythromycin–tretinoin lotion by the use of an optimization system **197**, 153
Brodin, A., see Scherlund, M. **211**, 37
Brodin, A., see Scherlund, M. **194**, 103
Brounéus, F., see Karami, K. **201**, 121
Bruni, R., see Maggi, L. **195**, 229
Bruno, V., see Bonina, F.P. **202**, 79
Buckton, G., J.W. Dove, P. Davies, Isothermal microcalorimetry and inverse phase gas chromatography to study small changes in powder surface properties **193**, 13
Buckton, G., see Hogan, S.E. **207**, 57
Buckton, G., see Lane, R.A. **207**, 49
Bugay, D.E., see Gandhi, R.B. **201**, 221
Bulgarelli, E., F. Forni, M.T. Bernabei, Effect of matrix composition and process conditions on casein–gelatin beads floating properties **198**, 157
Bult, A., see Nuijen, B. **194**, 261
Bum, J.-P., see Shin, S.-C. **209**, 37
Bush, D., see Jackson, S.J. **205**, 173
Bush, D., see Washington, N. **198**, 139
Bustamante, P., M.A. Peña, J. Barra, The modified extended Hansen method to determine partial solubility parameters of drugs containing a single hydrogen bonding group and their sodium derivatives: benzoic acid/Na and ibuprofen/Na **194**, 117
Butler, W.C., see Bloomfield, M.S. **206**, 55
Butula, I., see Lovrek, M. **200**, 59

Caetano, M.N.P., see Santos-Magalhães, N.S. **208**, 71
Calado, A., see Bettencourt, A. **197**, 161
Caliceti, P., F.M. Veronese, S. Lora, Polyphosphazene microspheres for insulin delivery **211**, 57
Çalış, S., see Tunçay, M. **195**, 179
Cal, K., see Gabiga, H. **199**, 1
Calvo, L.J., see Mlynek, G.M. **197**, 13
Calvo, M.B., see San Vicente, A. **208**, 13
Camber, O., see Crowley, K.J. **211**, 9
Camber, O., see Hedenus, P. **202**, 141
Cammarn, S.R., A. Sakr, Predicting dissolution via hydrodynamics: salicylic acid tablets in flow through cell dissolution **201**, 199
Campbell, L., see Birchall, J.C. **197**, 233
Caputo, O., see Marengo, E. **205**, 3
Caramella, C., see Bonferoni, M.C. **200**, 207
Cardoso, S.G., E.E.S. Schapoval, Microbiological assay for terbinafine hydrochloride in tablets and creams **203**, 109
Carelli, V., G. Di Colo, E. Nannipieri, B. Poli, M.F. Serafini, Polyoxyethylene-poly(methacrylic acid-co-methyl methacrylate) compounds for site-specific peroral delivery **202**, 103
Carpinelli, A., see Moresco, R.M. **204**, 101
Carteni, M., see Morana, A. **194**, 61
Carter, P.A., see Eilbeck, J. **195**, 7
Cartilier, L., see Chebli, C. **193**, 167
Cartwright, A., *New Drug Approval Process*' (*3rd ed.*), Edited by Richard Guarino, pp xxiii + 471, Dekker, New York, 2000. ISBN 0-8247-0308-1 **210**, 123
Casabo, V.G., see Ruiz-Carretero, P. **202**, 89
Cassanas, G., see Billon, A. **203**, 159
Cassidy, O.E., see Rouchotas, C. **195**, 1

Castro, M., see Bettencourt, A. **197**, 161
Cavalli, R., see Marengo, E. **205**, 3
Cavalli, R., see Miglietta, A. **210**, 61
Ceschel, G.C., P. Maffei, M.D.L. Moretti, S. Demontis, A.T. Peana, In vitro permeation through porcine buccal mucosa of *Salvia desoleana* Atzei & Picci essential oil from topical formulations **195**, 171
Chacón, M., see Molpeceres, J. **197**, 129
Chadha, R., see Jain, D.V.S. **201**, 1
Chang, J.J.-F., see Wu, P.-C. **209**, 87
Chang, J.-S., see Wu, P.-C. **209**, 87
Chang, S.-L., G.A. Hofmann, L. Zhang, L.J. Deftos, A.K. Banga, Transdermal iontophoretic delivery of salmon calcitonin **200**, 107
Chang, S.-Y., see Park, E.-S. **209**, 109
Chan, H.-K., see Chew, N.Y.K. **206**, 75
Chan, H.-K., see Chew, N.Y.K. **200**, 87
Chan, L.W., T.R.R. Kurup, A. Muthaiah, J.C. Thenmozhiyal, Interaction of *p*-hydroxybenzoic esters with beta-cyclodextrin **195**, 71
Chao, S.-C., see Chen, D. **203**, 141
Chaput, C., see Ruel-Gariépy, E. **203**, 89
Charlier, A., B. Leclerc, G. Couarraze, Release of mifepristone from biodegradable matrices: experimental and theoretical evaluations **200**, 115
Charman, W.N., see Khoo, S.-M. **205**, 65
Charman, W.N., see Lyons, K.C. **199**, 17
Chauhan, S., see Dobson, C.L. **195**, 63
Chebli, C., L. Cartilier, Effect of some physical parameters on the sustained drug-release properties of substituted amylose matrices **193**, 167
Chen, A., see Edge, S. **200**, 67
Chen, C.F., see Tsai, T.H. **193**, 21
Chen, D., R.-J. Tsay, H.-I. Lin, H. Chen, S.-C. Chao, H. Ku, Stabilization and sustained-release effect of Misoprostol with Methacrylate copolymer **203**, 141
Cheng, F.C., see Tsai, T.H. **193**, 21
Chen, H., see Chen, D. **203**, 141
Chenite, A., see Ruel-Gariépy, E. **203**, 89
Cherkaoui, I., V. Monticone, C. Vaution, C. Treiner, Coadsorption of the sodium salts of two steroid molecules at a silica/interface as induced by the adsorption of a cationic surfactant **201**, 71
Chevanne, F., see Clément, R. **203**, 227
Chew, N.Y.K., D.F. Bagster, H.-K. Chan, Effect of particle size, air flow and inhaler device on the aerosolisation of disodium cromoglycate powders **206**, 75
Chew, N.Y.K., H.-K. Chan, The effect of spacers on the delivery of metered dose aerosols of nedocromil sodium and disodium cromoglycate **200**, 87
Chiba, Y., see Morishita, M. **201**, 175
Chiba, Y., see Onuki, Y. **198**, 147
Chi, S.-C., see Park, E.-S. **209**, 109
Cho, C.-S., see Kim, I.-S. **211**, 1
Cho, C.-S., see Kim, I.-S. **205**, 165
Cho, C.-W., see Shin, S.-C. **193**, 213
Choi, H.-K., see Kim, J.-H. **196**, 105
Choi, H.-K., see Lee, J.-H. **196**, 75
Choi, J.-S., see Shin, S.-C. **209**, 37
Choi, S.-H., see Cui, J.-H. **210**, 51
Choi, S.H., T.G. Park, Hydrophobic ion pair formation between leuprolide and sodium oleate for sustained release from biodegradable polymeric microspheres **203**, 193
Choi, Y.M., see Li, L. **199**, 65
Chong, S., see Moore, V.A. **210**, 15
Chong, S., see Moore, V.A. **210**, 29
Chowdhry, B.Z., see Michael, Y. **200**, 279
Chowdhury, D.K., A.K. Mitra, Kinetics of in vitro release of a model nucleoside deoxyuridine from crosslinked insoluble collagen and collagen–gelatin microspheres **193**, 113
Chow, M.Y., see Neau, S.H. **199**, 129
Cho, Y.-J., see Kim, J.-H. **196**, 105
Christensen, K., see Hancock, B.C. **209**, 27
Chulia, D., see Vachon, M.G. **198**, 251
Chu, W.A., see Mitra, R. **205**, 127
Clas, S.-D., see Hancock, B.C. **209**, 27
Clément, P., C. Laugel, J.-P. Marty, In vitro release of caffeine from concentrated W/O emulsions: effect of formulation parameters **207**, 7
Clément, R., J.-M. Malinovsky, P. Le Corre, G. Dollo, F. Chevanne, R. Le Verge, Spinal biopharmaceutics of bupivacaine and lidocaine by microdialysis after their simultaneous administration in rabbits **203**, 227
Cócera, M., O. López, J.L. Parra, M.E. Mercadé, J. Guinea, A. de la Maza, Protective effect caused by the exopolymer excreted by *Pseudoalteromonas antarctica* NF_3 on liposomes against the action of octyl glucoside **207**, 39
Coester, C., J. Kreuter, H. von Briesen, K. Langer, Preparation of avidin-labelled gelatin nanoparticles as carriers for biotinylated peptide nucleic acid (PNA) **196**, 147
Coester, C., see Weber, C. **194**, 91
Collett, J.H., see Bentley, M.V.L.B. **193**, 49
Collett, J.H., see Lopez, R.F.V. **200**, 127
Collett, J.H., see Whitehead, L. **210**, 45
Collins, M.P., see Whitaker, M. **205**, 79
Concheiro, A., see Alvarez-Lorenzo, C. **197**, 107
Concheiro, A., see Gutiérrez de Rubalcava, C. **203**, 99
Conte, U., see Maggi, L. **195**, 229
Conti, B., see Perugini, P. **196**, 51
Cooke, R., see Mizushima, J. **197**, 193
Copland, M.J., T. Rades, N.M. Davies, Hydration of lipid films with an aqueous solution of Quil A: a simple method for the preparation of immune-stimulating complexes **196**, 135
Cortell, C., see López, A. **202**, 133
Cortell-Ivars, C., see López-Castellano, A. **203**, 245
Couarraze, G., see Charlier, A. **200**, 115
Couarraze, G., see Maillard-Salin, D.G. **200**, 121
Couarraze, G., see Maillard-Salin, D.G. **199**, 29
Cox, P.J., G.I. Gilmour, S.M. MacManus, Hydrogen bonding in salicylsalicylic acid (salsalate) crystals **204**, 133
Cox, P.J., J.L. Wardell, Studies of polymorphism in three compounds by single crystal X-ray diffraction **194**, 147
Cox, P.J., K.A. Khan, D.L. Munday, J. Sujja-areevath, Devel-

opment and evaluation of a multiple-unit oral sustained release dosage form for *S*(+)-ibuprofen: preparation and release kinetics **193**, 73
Cox, P.J., see Munday, D.L. **203**, 179
Craig, D.Q.M., see Arunothayanun, P. **201**, 7
Craig, D.Q.M., see Robson, H. **201**, 211
Craig, D.Q.M., see Robson, H. **195**, 137
Craig, D.Q.M., see Wissing, S. **199**, 141
Crommelin, D.J.A., see Bos, G.W. **211**, 79
Crowley, K.J., R.T. Forbes, P. York, H. Nyqvist, O. Camber, Drug-fatty acid salt with wax-like properties employed as binder in melt granulation **211**, 9
Cruz, R., see Aceves, J.M. **195**, 45
Cui, J.-H., J.-S. Goh, P.-H. Kim, S.-H. Choi, B.-J. Lee, Survival and stability of bifidobacteria loaded in alginate poly-*l*-lysine microparticles **210**, 51
Cuña, M., J.L. Vila Jato, D. Torres, Controlled-release liquid suspensions based on ion-exchange particles entrapped within acrylic microcapsules **199**, 151

Dabrowska, E., see Sznitowska, M. **202**, 161
Dahlin, M., E. Björk, Nasal absorption of (S)-UH-301 and its transport into the cerebrospinal fluid of rats **195**, 197
Damen, J.M.A., see van Maanen, M.J. **200**, 187
Damen, J.M.A., see van Maanen, R.J. **196**, 85
Dando, S.A., see Moore, V.A. **210**, 15
Dando, S.A., see Moore, V.A. **210**, 29
Dastmalchi, S., M. Barzegar-Jalali, Relationship between potency and boiling point of general anesthetics: a thermodynamic consideration **202**, 41
Davies-Cutting, C., see Michael, Y. **200**, 279
Davies, N.M., see Alany, R.G. **196**, 141
Davies, N.M., see Bibby, D.C. **197**, 1
Davies, N.M., see Copland, M.J. **196**, 135
Davies, P., see Buckton, G. **193**, 13
Davis, A.F., see Raghavan, S.L. **193**, 231
Davis, S.S., see Dobson, C.L. **195**, 63
Davis, S.S., see Govender, T. **199**, 95
De Brabander, C., C. Vervaet, J.P. Görtz, J.P. Remon, J.A. Berlo, Bioavailability of ibuprofen from matrix mini-tablets based on a mixture of starch and microcrystalline wax **208**, 81
De Brabander, C., C. Vervaet, L. Fiermans, J.P. Remon, Matrix mini-tablets based on starch/microcrystalline wax mixtures **199**, 195
de Caprariis, P., see Bonina, F.P. **202**, 79
De Clercq, E., see Van Gelder, J. **205**, 93
DeCrosta, M.T., J.B. Schwartz, R.J. Wigent, K. Marshall, Thermodynamic analysis of compact formation; compaction, unloading, and ejection: I. Design and development of a compaction calorimeter and mechanical and thermal energy determinations of powder compaction **198**, 113
Deforge, L., see Koumenis, I.L. **198**, 83
Deftos, L.J., see Chang, S.-L. **200**, 107
Degim, I.T., see Pugh, W.J. **197**, 203
de la Maza, A., see Cócera, M. **207**, 39
DellaVecchia, S.A., see Sloan, K.B. **205**, 53
D'Emanuele, A., see Milhem, O.M. **197**, 239
Demontis, S., see Ceschel, G.C. **195**, 171
De Pasquale, A., see Saija, A. **199**, 39
Derom, E., see Borgström, L. **193**, 227
De Rosa, M., see Morana, A. **194**, 61
De Rosa, R., see Morana, A. **194**, 61
Deschatelets, L., see Patel, G.B. **194**, 39
de Smidt, P.C., T. Rades, Direct detection of dissolution of ^{14}C-labeled compounds into an oil phase by the fat scintillation proximity method **196**, 187
De, T.K., see Gaur, U. **202**, 1
Deutsch, D., see Robson, H. **201**, 211
Deutsch, D., see Robson, H. **195**, 137
Devleeschouwer, M.J., see Semdé, R. **197**, 181
Devleeschouwer, M.J., see Semdé, R. **197**, 169
Díez Peña, E., see Frutos Cabanillas, P. **209**, 15
Dickinson, P.A., see Jones, B.G. **195**, 17
Dickinson, P.A., see Seville, P.C. **195**, 13
Di Colo, G., see Carelli, V. **202**, 103
Di Cristofaro, R., see Di Martino, P. **197**, 95
Didriksen, E., see Nielsen, H.W. **204**, 35
Di Lernia, I., see Morana, A. **194**, 61
Di Martino, P., R. Di Cristofaro, C. Barthélémy, E. Joiris, G. Palmieri Filippo, M. Sante, Improved compression properties of propyphenazone spherical crystals **197**, 95
Dinh, S., see Anigbogu, A. **200**, 195
Diseroad, B.A., see Stephenson, G.A. **198**, 167
Dobrucki, R., see Radomska, A. **196**, 131
Dobson, C.L., S.S. Davis, S. Chauhan, R.A. Sparrow, I.R. Wilding, Does the site of intestinal delivery of oleic acid alter the ileal brake response? **195**, 63
Doesburg Smits, K., see van Maanen, M.J. **200**, 187
Dokka, S., D. Toledo, X. Shi, J. Ye, Y. Rojanasakul, High-efficiency gene transfection of macrophages by lipoplexes **206**, 97
Dollo, G., see Clément, R. **203**, 227
Dove, J.W., see Buckton, G. **193**, 13
Driot, J.-Y., see Séchoy, O. **207**, 109
D. Ticehurst, M., P. A. Basford, C. I. Dallman, T. M. Lukas, P. V. Marshall, G. Nichols, D. Smith, Characterisation of the influence of micronisation on the crystallinity and physical stability of revatropate hydrobromide **193**, 247
Dubois, J., see Some, I.T. **198**, 39
Duc Hanh, B., R.H.H. Neubert, S. Wartewig, Investigation of drug release from suspension using FTIR-ATR technique: part I. Determination of effective diffusion coefficient of drugs **204**, 145
Duc Hanh, B., R.H.H. Neubert, S. Wartewig, Investigation of drug release from suspension using FTIR-ATR technique: part II. Determination of dissolution coefficient of drugs **204**, 151
Duclos, R., see Skiba, M. **198**, 1
Dufes, C., see McPhail, D. **200**, 73
Dunn, R.L., see Ravivarapu, H.B. **194**, 181
du Plessis, J., see Beetge, E. **193**, 261
Duro, R., see Gutiérrez de Rubalcava, C. **203**, 99
Durrani, M.J., see Neau, S.H. **199**, 129

Dwivedi, A.K., see Ghosal, S. **194**, 15
Dwivedi, A.K., see Paliwa, J.K. **197**, 213

Ebube, N.K., G. Owusu-Ababio, C.M. Adeyeye, Preformulation studies and characterization of the physicochemical properties of amorphous polymers using artificial neural networks **196**, 27
Eccleston, G.M., M.K. Behan-Martin, G.R. Jones, E. Towns-Andrews, Synchrotron X-ray investigations into the lamellar gel phase formed in pharmaceutical creams prepared with cetrimide and fatty alcohols **203**, 127
Edge, S., D.F. Steele, A. Chen, M.J. Tobyn, J.N. Staniforth, The mechanical properties of compacts of microcrystalline cellulose and silicified microcrystalline cellulose **200**, 67
Edwards-Lévy, F., see Pariot, N. **211**, 19
Eguchi, T., see Kasai, T. **204**, 53
Eguchi, T., see Yuasa, H. **209**, 69
Ehtezazi, T., see Govender, T. **199**, 95
Eilbeck, J., G. Rowley, P.A. Carter, E.J. Fletcher, Effect of contamination of pharmaceutical equipment on powder triboelectrification **195**, 7
Eissens, A.C.E., see Steendam, R. **204**, 23
Ek, R., see Hedenus, P. **202**, 141
Ek, R., see Strømme Mattsson, M. **199**, 179
El-Kattan, A.F., C.S. Asbill, B.B. Michniak, The effect of terpene enhancer lipophilicity on the percutaneous permeation of hydrocortisone formulated in HPMC gel systems **198**, 179
El Maghraby, G.M.M., A.C. Williams, B.W. Barry, Oestradiol skin delivery from ultradeformable liposomes: refinement of surfactant concentration **196**, 63
El Maghraby, G.M.M., A.C. Williams, B.W. Barry, Skin delivery of oestradiol from lipid vesicles: importance of liposome structure **204**, 159
El-Thaher, T., see Albarghouthi, M. **206**, 23
Emås, M., H. Nyqvist, Methods of studying aging and stabilization of spray-congealed solid dispersions with carnauba wax. 1. Microcalorimetric investigation **197**, 117
Endo, H., see Ishikawa, T. **202**, 173
Endruschat, J., K. Henschke, Bench scale manufacture of multilamellar liposomes using a newly developed multistage pressure filtration device **196**, 151
Engel, G.L., N.A. Farid, M.M. Faul, L.A. Richardson, L.L. Winneroski, Salt form selection and characterization of LY333531 mesylate monohydrate **198**, 239
Ercan, M.T., see Tunçay, M. **195**, 179
Espinoza, R., E. Hong, L. Villafuerte, Influence of admixed citric acid on the release profile of pelanserin hydrochloride from HPMC matrix tablets **201**, 165
Estes, J.V., see Sloan, K.B. **205**, 53
Evans, B.A., see Neau, S.H. **199**, 129

Fahr, A., see Welz, C. **196**, 251
Fara, D.A., see Albarghouthi, M. **206**, 23
Farid, N.A., see Engel, G.L. **198**, 239
Fariña, J., see Llabrés, M. **204**, 61
Farkas, E., R. Zelkó, Z. Németh, J. Pálinkás, S. Marton, I. Rácz, The effect of liquid crystalline structure on chlorhexidine diacetate release **193**, 239
Farr, S.J., S.J. Warren, P. Lloyd, J.K. Okikawa, J.A. Schuster, A.M. Rowe, R.M. Rubsamen, G. Taylor, Comparison of in vitro and in vivo efficiencies of a novel unit-dose liquid aerosol generator and a pressurized metered dose inhaler **198**, 63
Fatouros, A., B. Sjöström, Recombinant factor VIII SQ — the influence of formulation parameters on structure and surface adsorption **194**, 69
Faucci, M.T., see Mura, P. **193**, 85
Faul, M.M., see Engel, G.L. **198**, 239
Fawaz, F., see Guyot, M. **204**, 171
Fazio, F., see Moresco, R.M. **204**, 101
Fecko, C.J., see Perkins, W.R. **200**, 27
Feher, M., E. Sourial, J.M. Schmidt, A simple model for the prediction of blood–brain partitioning **201**, 239
Fell, J.T., see Whitehead, L. **210**, 45
Fernandes, C., see Veiga, F. **202**, 165
Ferrari, F., see Bonferoni, M.C. **200**, 207
Ferreira, L., M.M. Vidal, M.H. Gil, Evaluation of poly(2-hydroxyethyl methacrylate) gels as drug delivery systems at different pH values **194**, 169
Ferrero, C., A. Muñoz-Ruiz, M.R. Jiménez-Castellanos, Fronts movement as a useful tool for hydrophilic matrix release mechanism elucidation **202**, 21
Fice, D., see Yeung, P.K.F. **204**, 17
Fiermans, L., see De Brabander, C. **199**, 195
Filipovic-Grcic, J., see Voinovich, D. **203**, 235
Finlay, W.H., M.G. Gehmlich, Inertial sizing of aerosol inhaled from two dry powder inhalers with realistic breath patterns versus constant flow rates **210**, 83
Finlay, W.H., see Lee, Z. **199**, 7
Fleming, L.P., see Patel, G.B. **194**, 39
Fletcher, E.J., see Eilbeck, J. **195**, 7
Flig, E., T.W. Hermann, M. Zabel, Is bisacodyl absorbed at all from suppositories in man? **196**, 11
Flonta, M.L., see Movileanu, L. **205**, 135
Florence, A.T., Editorial **205**, 1
Florence, A.T., see Arunothayanun, P. **201**, 7
Florence, A.T., see Shah, D.S. **208**, 41
Forbes, R.T., see Crowley, K.J. **211**, 9
Ford, J.L., see Garekani, H.A. **208**, 101
Ford, J.L., see Garekani, H.A. **208**, 87
Forni, F., see Bulgarelli, E. **198**, 157
Forni, F., see Leo, E. **196**, 1
Foster, K.A., M.L. Avery, M. Yazdanian, K.L. Audus, Characterization of the Calu-3 cell line as a tool to screen pulmonary drug delivery **208**, 1
Foster, R.T., see Mostafavi, S.A. **202**, 97
Friedman, M., see Baluom, M. **193**, 265
Friedman, M., see Katzhendler, I. **200**, 161
Frijlink, H.W., see Steendam, R. **204**, 23
Frijlink, H.W., see van Veen, B. **203**, 71
Frokjaer, S., see Bjerregaard, S. **193**, 1
Frutos Cabanillas, P., E. Díez Peña, J.M. Barrales-Rienda, G. Frutos, Validation and in vitro characterization of antibiotic-loaded bone cement release **209**, 15

Frutos, G., see Frutos Cabanillas, P. **209**, 15
Fujii, M., N. Hori, K. Shiozawa, K. Wakabayashi, E. Kawahara, M. Matsumoto, Effect of fatty acid Esters on permeation of ketoprofen through hairless rat skin **205**, 117
Fukui, E., N. Miyamura, K. Uemura, M. Kobayashi, Preparation of enteric coated timed-release press-coated tablets and evaluation of their function by in vitro and in vivo tests for colon targeting **204**, 7
Furrer, P., B. Plazonnet, J.M. Mayer, R. Gurny, Application of in vivo confocal microscopy to the objective evaluation of ocular irritation induced by surfactants **207**, 89

Gabiga, H., K. Cal, S. Janicki, Effect of penetration enhancers on isosorbide dinitrate penetration through rat skin from a transdermal therapeutic system **199**, 1
Gabriel, L., see Miglietta, A. **210**, 61
Gabriëls, M., see Brisaert, M. **197**, 153
Galántai, R., I. Bárdos-Nagy, The interaction of human serum albumin and model membranes **195**, 207
Galli Kienle, M., see Moresco, R.M. **204**, 101
Gamazo, C., see Prior, S. **196**, 115
Gander, B., see Prior, S. **196**, 115
Gandhi, R.B., J.B. Bogardus, D.E. Bugay, R.K. Perrone, M.A. Kaplan, Pharmaceutical relationships of three solid state forms of stavudine **201**, 221
Garekani, H.A., J.L. Ford, M.H. Rubinstein, A.R. Rajabi-Siahboomi, Highly compressible paracetamol: I: crystallization and characterization **208**, 87
Garekani, H.A., J.L. Ford, M.H. Rubinstein, A.R. Rajabi-Siahboomi, Highly compressible paracetamol — II. Compression properties **208**, 101
Garnett, M.C., see Govender, T. **199**, 95
Gasco, M.R., see Marengo, E. **205**, 3
Gascón, A.R., see San Vicente, A. **208**, 13
Gašperlin, M., L. Tušar, M. Tušar, J. Šmid-Korbar, J. Zupan, J. Kristl, Viscosity prediction of lipophilic semisolid emulsion systems by neural network modelling **196**, 37
Gaur, U., S.K. Sahoo, T.K. De, P.C. Ghosh, A. Maitra, P.K. Ghosh, Biodistribution of fluoresceinated dextran using novel nanoparticles evading reticuloendothelial system **202**, 1
Gehmlich, M.G., see Finlay, W.H. **210**, 83
Genta, I., see Perugini, P. **196**, 51
Gershanik, T., E. Haltner, C.-M. Lehr, S. Benita, Charge-dependent interaction of self-emulsifying oil formulations with Caco-2 cells monolayers: binding, effects on barrier function and cytotoxicity **211**, 29
Gessner, A., R. Waicz, A. Lieske, B.-R. Paulke, K. Mäder, R.H. Müller, Nanoparticles with decreasing surface hydrophobicities: influence on plasma protein adsorption **196**, 245
Gheyas, F., see Neau, S.H. **199**, 129
Ghosal, S., B.N. KrishnaPrasad, M. Khanna, A.K. Dwivedi, S. Singh, A. Kumar, S.B. Katti, 3′-Deoxyribonucleosides and their derivatives as anti-amoebic agents **194**, 15
Ghosh, P.C., see Gaur, U. **202**, 1
Ghosh, P.K., see Gaur, U. **202**, 1
Gilbert, D.L., see Badawy, S.I.F. **198**, 51
Gilhar, A., see Sintov, A. **194**, 125
Gillard, J., see Baras, B. **200**, 133
Gill, D.A., see Washington, N. **198**, 139
Gil, M.H., see Ferreira, L. **194**, 169
Gilmour, G.I., see Cox, P.J. **204**, 133
Gizurarson, S., see Lindhardt, K. **205**, 159
Główka, F.K., Stereoselective pharmacokinetics of ibuprofen and its lysinate from suppositories in rabbits **199**, 159
Gobbo, C., see Moresco, R.M. **204**, 101
Goh, J.-S., see Cui, J.-H. **210**, 51
Gohla, S.H., see Jenning, V. **205**, 15
Gohla, S.H., see Jenning, V. **199**, 167
Gohla, S., see Jenning, V. **196**, 219
Gómez-Amoza, J.L., see Alvarez-Lorenzo, C. **197**, 107
Gómez, C., see Blanco, M.D. **202**, 29
Goosen, C., see Beetge, E. **193**, 261
Goosen, C., see Hadgraft, J. **207**, 31
Gorko, M.A., see Badawy, S.I.F. **198**, 51
Görtz, J.P., see De Brabander, C. **208**, 81
Gorukanti, S., see Li, L. **199**, 65
Goulding, P.A., see Whitaker, M. **205**, 79
Govender, T., T. Riley, T. Ehtezazi, M.C. Garnett, S. Stolnik, L. Illum, S.S. Davis, Defining the drug incorporation properties of PLA–PEG nanoparticles **199**, 95
Grabnar, I., see Voinovich, D. **203**, 235
Grau, M.J., O. Kayser, R.H. Müller, Nanosuspensions of poorly soluble drugs — reproducibility of small scale production **196**, 155
Gray, S., see Michael, Y. **200**, 279
Griffiths, G., see Lundberg, B.B. **205**, 101
Grist, N., see Patel, D. **200**, 271
Gröning, R., U. Kuhland, Pulsed release of nitroglycerin from transdermal drug delivery systems **193**, 57
Guinea, J., see Cócera, M. **207**, 39
Guirguis, S., see Ruel-Gariépy, E. **203**, 89
Gumbleton, M., see Birchall, J.C. **197**, 221
Gumbleton, M., see Birchall, J.C. **197**, 233
Gumbleton, M., see Jones, B.G. **195**, 17
Gumbleton, M., see Ramsay, E. **210**, 97
Guo, J., Q. Ping, G. Sun, C. Jiao, Lecithin vesicular carriers for transdermal delivery of cyclosporin A **194**, 201
Gupta, A.K., S. Madan, D.K. Majumdar, A. Maitra, Ketorolac entrapped in polymeric micelles: preparation, characterisation and ocular anti-inflammatory studies **209**, 1
Gupta, S.K., see Sathyan, G. **204**, 47
Gurny, R., see Furrer, P. **207**, 89
Gust, R., see Krause, K.P. **196**, 169
Gutiérrez de Rubalcava, C., J.L. Rodriguez, R. Duro, C. Alvarez-Lorenzo, A. Concheiro, B. Seijo, Interactions between liposomes and hydroxypropylmethylcellulose **203**, 99
Gutpa, R.C., see Paliwa, J.K. **197**, 213
Güven, O., see Şen, M. **203**, 149
Guyot, M., F. Fawaz, Design and in vitro evaluation of adhesive matrix for transdermal delivery of propranolol **204**, 171

Guzmán, M., see Molpeceres, J. **197**, 129
Guzzetta, A., see Wu, S.-L. **200**, 1

Hadgraft, J., C. Valenta, pH, pK_a and dermal delivery **200**, 243
Hadgraft, J., J. Plessis, C. Goosen, The selection of non-steroidal anti-inflammatory agents for dermal delivery **207**, 31
Hadgraft, J., see Birchall, J.C. **197**, 233
Hadgraft, J., see Iervolino, M. **198**, 229
Hadgraft, J., see Pellett, M.A. **193**, 27
Hadgraft, J., see Pugh, W.J. **197**, 203
Hadgraft, J., see Raghavan, S.L. **193**, 231
Hadgraft, J., see Ramsay, E. **210**, 97
Hadgraft, J., see Valenta, C. **197**, 77
Hahn, H., see Schöler, N. **196**, 235
Hahn, M., see Park, E.-S. **209**, 109
Haltner, E.G., see Kneuer, C. **196**, 257
Haltner, E., see Gershanik, T. **211**, 29
Hanawa, T., E. Muramatsu, K. Asakawa, M. Suzuki, M. Tanaka, K. Kawano, T. Seki, K. Juni, S. Nakajima, Investigation of the release behavior of diethylhexyl phthalate from the polyvinyl-chloride tubing for intravenous administration **210**, 109
Hancock, B.C., S.-D. Clas, K. Christensen, Micro-scale measurement of the mechanical properties of compressed pharmaceutical powders. 1: The elasticity and fracture behavior of microcrystalline cellulose **209**, 27
Han, J., Y. Il Yeom, Specific gene transfer mediated by galactosylated poly-L-lysine into hepatoma cells **202**, 151
Han, K.S., see Kim, E.J. **194**, 193
Hanocq, M., see Some, I.T. **198**, 39
Hansen, H.J., see Lundberg, B.B. **205**, 101
Hansson, H., see Ljunggren, L. **202**, 71
Hanus, R., see Some, I.T. **198**, 39
Harashima, H., see Ishida, T. **205**, 183
Harding, D.R.K., see Shantha, K.L. **207**, 65
Hauck, G., see Loth, H. **209**, 95
Hayashi, J., see Lentz, K.A. **200**, 41
Hayashi, K., see Kogure, K. **210**, 117
Hayashi, T., see Miyazaki, S. **204**, 127
Heald, D.L., see Lee, Z. **199**, 7
Heard, C.M., see Allender, C.J. **195**, 39
Hechenleitner, A.A.W., see Uesu, N.Y. **206**, 85
Heck, A.J.R., see van Maanen, M.J. **200**, 187
Hedenus, P., M. Strømme Mattsson, G.A. Niklasson, O. Camber, R. Ek, Characterisation of instantaneous water absorption properties of pharmaceutical excipients **202**, 141
Hedenus, P., see Strømme Mattsson, M. **199**, 179
Heinämäki, J., see Krogars, K. **199**, 187
Hennink, W.E., see Bos, G.W. **211**, 79
Henrar, R.E.C., see Nuijen, B. **194**, 261
Henry, B., see Reason, M. **195**, 25
Henschke, K., see Endruschat, J. **196**, 151
Henschke, K., see Pietzyk, B. **196**, 215
Herbert, C., see Perkins, W.R. **200**, 27
Hermann, T.W., see Flig, E. **196**, 11
Hernandez, E., see Aceves, J.M. **195**, 45
Hernández, R.M., see San Vicente, A. **208**, 13
Herráez-Domínguez, M., see López-Castellano, A. **203**, 245
Herráez, M., see López, A. **202**, 133
Hester, K.C., see Kwok, K.Y. **203**, 81
Higashiyama, K., see Obata, Y. **198**, 191
Hildebrand, G.E., J.W. Tack, Microencapsulation of peptides and proteins **196**, 173
Hileman, G.A., see Neau, S.H. **199**, 129
Hincal, A.A., see Tunçay, M. **195**, 179
Hirota, S., see Shimada, K. **203**, 255
Hirsh, D.J., see Perkins, W.R. **200**, 27
Hirst, P.H., see Newman, S.P. **208**, 49
Hıncal, A.A., see Şenel, S. **193**, 197
Hoffman, M., see Lamprecht, A. **196**, 177
Hofmann, G.A., see Chang, S.-L. **200**, 107
Hogan, S.E., G. Buckton, The quantification of small degrees of disorder in lactose using solution calorimetry **207**, 57
Hoganson, D.A., see Rensberger, K.L. **207**, 71
Holmqvist, P., see Scherlund, M. **194**, 103
Hombreiro Pérez, M., see Lamprecht, A. **196**, 177
Hong, E., see Espinoza, R. **201**, 165
Hori, N., see Fujii, M. **205**, 117
Hou, W.-M., see Miyazaki, S. **204**, 127
Hsei, V., see Koumenis, I.L. **198**, 83
Huang, Y.-B., see Wu, P.-C. **209**, 87
Hu, C., D.G. Rhodes, Erratum to 'Proniosomes: A Novel Drug Carrier Preparation': [Int. J. Pharm. 185 (1999) 23–35] **206**, 109
Huizhou, L., see Yuchun, X. **196**, 21
Hu, J., see Wu, S.-L. **200**, 1
Hung, L.C., see Tsai, T.H. **193**, 21
Hu, Q., W. Liang, J. Bao, Q. Ping, Enhanced transdermal delivery of tetracaine by electroporation **202**, 121
Hussain, N., *Bioadhesive Drug Delivery Systems: Fundamentals. novel approaches and development*: Edited by E. Mathiowitz, D.E. Chickering III and C-M. Lehr. ISBN 0-8247-1995-6 **205**, 201
Hwang, S., see Sathyan, G. **204**, 47
Hyvärinen, V., see Silvennoinen, R. **199**, 205

I. Dallman, C., see D. Ticehurst, M. **193**, 247
Iervolino, M., S.L. Raghavan, J. Hadgraft, Membrane penetration enhancement of ibuprofen using supersaturation **198**, 229
Ikechukwu Ugwoke, M., G. Kaufmann, N. Verbeke, R. Kinget, Intranasal bioavailability of apomorphine from carboxymethylcellulose-based drug delivery systems **202**, 125
Ikeda, M., see Kamba, M. **208**, 61
İkinci, G., see Şenel, S. **193**, 197
İlker, S.S., see Öztürk, F. **204**, 97
İlker, S.S., see Öztürk, F. **204**, 91
Illing, A., see Lukowski, G. **196**, 201
Illum, L., see Govender, T. **199**, 95
Il Yeom, Y., see Han, J. **202**, 151

İnan, Ü., see Öztürk, F. **204**, 97
İnan, Ü., see Öztürk, F. **204**, 91
Ippolito, R., see Bonina, F.P. **202**, 79
Irache, J.M., see Prior, S. **196**, 115
Irwin, W.J., see Moore, V.A. **210**, 15
Irwin, W.J., see Moore, V.A. **210**, 29
Irwin, W.J., see Smith, J.C. **210**, 69
Isel, H., see Bittner, B. **205**, 195
Ishida, T., H. Kojima, H. Harashima, H. Kiwada, Biodistribution of liposomes and C3 fragments associated with liposomes: evaluation of their relationship **205**, 183
Ishikawa, T., Y. Watanabe, K. Takayama, H. Endo, M. Matsumoto, Effect of hydroxypropylmethylcellulose (HPMC) on the release profiles and bioavailability of a poorly water-soluble drug from tablets prepared using macrogol and HPMC **202**, 173
Ishiwaki, N., see Kasai, T. **204**, 53
Ishiwaki, N., see Yuasa, H. **209**, 69
Ismail, M.W., see Monem, A.S. **198**, 29
Isowa, K., see Obata, Y. **198**, 191
Isowa, K., see Onuki, Y. **198**, 147
Itai, S., see Kobayashi, Y. **193**, 137
Itai, S., see Miwa, A. **195**, 81
Itoh, T., see Kogure, K. **210**, 117
Ito, S., see Kobayashi, Y. **193**, 137
Iwase, H., see Kaneo, Y. **201**, 59
Iwatsu, M., see Miyazaki, S. **204**, 127
Iwatsuru, M., see Moribe, K. **201**, 37
Iwatsuru, M., see Moribe, K. **193**, 97

Jachowicz, R., E. Nürnberg, B. Pieszczek, B. Kluczykowska, A. Maciejewska, Solid dispersion of ketoprofen in pellets **206**, 13
Jackson, S.J., D. Bush, N. Washington, A.C. Perkins, Effect of resin surface charge on gastric mucoadhesion and residence of cholestyramine **205**, 173
Jackson, S.J., see Washington, N. **198**, 139
Jacob, M., see Billon, A. **203**, 159
Jacobs, C., O. Kayser, R.H. Müller, Nanosuspensions as a new approach for the formulation for the poorly soluble drug tarazepide **196**, 161
Jain, A.K., R. Panchagnula, Skeletal drug delivery systems **206**, 1
Jain, D.V.S., N. Kashid, S. Kapoor, R. Chadha, Enthalpies of solution of ampicillin, amoxycillin and their binary mixtures at 310.15 K **201**, 1
James, S.L., see MacAdam, A.B. **195**, 147
Jamieson, A., see Yeung, P.K.F. **204**, 17
Jang, M.-K., see Jeon, H.-J. **207**, 99
Janicki, S., see Gabiga, H. **199**, 1
Janicki, S., see Sznitowska, M. **202**, 161
Janoff, A.S., see Perkins, W.R. **200**, 27
Jasti, B.R., S.-l. Zhou, R.C. Mehta, X. Li, Permeability of antisense oligonucleotide through porcine buccal mucosa **208**, 35
Jenning, V., A.F. Thünemann, S.H. Gohla, Characterisation of a novel solid lipid nanoparticle carrier system based on binary mixtures of liquid and solid lipids **199**, 167
Jenning, V., K. Mäder, S.H. Gohla, Solid lipid nanoparticles (SLN™) based on binary mixtures of liquid and solid lipids: a ^{1}H-NMR study **205**, 15
Jenning, V., S. Gohla, Comparison of wax and glyceride solid lipid nanoparticles (SLN®) **196**, 219
Jeong, Y.-I., see Jeon, H.-J. **207**, 99
Jeong, Y.-I., see Kim, I.-S. **211**, 1
Jeong, Y.-I., see Kim, I.-S. **205**, 165
Jeong, Y.-I., see Kim, I.-S. **205**, 109
Jeong, Y.-I., see Ryu, J.-G. **200**, 231
Jeon, H.-J., Y.-I. Jeong, M.-K. Jang, Y.-H. Park, J.-W. Nah, Effect of solvent on the preparation of surfactant-free poly(DL-lactide-co-glycolide) nanoparticles and norfloxacin release characteristics **207**, 99
Jestin, A., see Torché, A.-M. **201**, 15
Jiang, H.L., K.J. Zhu, Pulsatile protein release from a laminated device comprising of polyanhydrides and pH-sensitive complexes **194**, 51
Jiao, C., see Guo, J. **194**, 201
Jiayong, C., see Yuchun, X. **196**, 21
Jiménez-Castellanos, M.R., see Ferrero, C. **202**, 21
Jiskoot, W., see Bos, G.W. **211**, 79
Joiris, E., see Di Martino, P. **197**, 95
Jones, B.G., M. Gumbleton, I.W. Kellaway, P.A. Dickinson, Microcalorimetry does not predict the cellular phagocytosis of latex microspheres **195**, 17
Jones, G.R., see Eccleston, G.M. **203**, 127
Jorissen, M., see Uchenna Agu, R. **193**, 219
Jorissen, M., see Ugwoke, M.I. **205**, 43
Joshi, A.B., E. Rus, L.E. Kirsch, The degradation pathways of glucagon in acidic solutions **203**, 115
Jouan, H., see Torché, A.-M. **201**, 15
Julianto, T., K.H. Yuen, A.M. Noor, Improved bioavailability of vitamin E with a self emulsifying formulation **200**, 53
Jun, H.W., see Kang, L. **206**, 35
Juni, K., see Hanawa, T. **210**, 109
Junping, W., Y. Maitani, K. Takayama, T. Nagai, In vivo evaluation of doxorubicin carried with long circulating and remote loading proliposome **203**, 61

Kachrimanis, K., see Nikolakakis, I. **201**, 79
Kajita, M., see Morishita, M. **201**, 175
Kamata, K., see Maitani, Y. **200**, 17
Kamba, M., Y. Seta, A. Kusai, M. Ikeda, K. Nishimura, A unique dosage form to evaluate the mechanical destructive force in the gastrointestinal tract **208**, 61
Kanada, K., see Muramatsu, M. **199**, 77
Kanaya, Y., see Muramatsu, M. **199**, 77
Kanaya, Y., see Yuasa, H. **203**, 203
Kaneo, Y., T. Ueno, T. Tanaka, H. Iwase, Y. Yamaguchi, T. Uemura, Pharmacokinetics and biodisposition of fluorescein-labeled arabinogalactan in rats **201**, 59
Kaneshige, J., see Kasai, T. **204**, 53
Kaneshige, J., see Yuasa, H. **209**, 69

Kangas, M., see Kortesuo, P. **200**, 223
Kangasniemi, I., see Ahola, M. **195**, 219
Kangasniemi, I., see Kortesuo, P. **200**, 223
Kang, L., H.W. Jun, J.W. McCall, Physicochemical studies of lidocaine–menthol binary systems for enhanced membrane transport **206**, 35
Kanikkannan, N., J. Singh, P. Ramarao, Transdermal iontophoretic delivery of timolol maleate in albino rabbits **197**, 69
Kanık, A.E., see Yuksel, N. **209**, 57
Kanwar, M., see Kaur, I.P. **199**, 119
Kaplan, M.A., see Gandhi, R.B. **201**, 221
Kapoor, S., see Jain, D.V.S. **201**, 1
Karami, K., N. Merclin, F. Brounéus, P. Beronius, On iontophoretic delivery enhancement: ionization and transport properties of lidocaine hydrochloride in aqueous propylene glycol **201**, 121
Karhu, M., J. Kuikka, T. Kauppinen, K. Bergström, M. Vidgren, Pulmonary deposition of lactose carriers used in inhalation powders **196**, 95
Kasai, T., see Yuasa, H. **209**, 69
Kasai, T., T. Eguchi, N. Ishiwaki, J. Kaneshige, T. Ozeki, H. Yuasa, Application of acid-treated yeast cell wall (AYC) as a pharmaceutical additive: I. AYC as a novel coating material **204**, 53
Kasbohm, J., see Lukowski, G. **196**, 201
Kashid, N., see Jain, D.V.S. **201**, 1
Kaş, H.S., see Tunçay, M. **195**, 179
Kaş, S., see Şenel, S. **193**, 197
Katare, Y.K., see Vyas, S.P. **210**, 1
Katti, S.B., see Ghosal, S. **194**, 15
Katzfey, U., see Schöler, N. **196**, 235
Katzhendler, I., K. Mäder, M. Friedman, Structure and hydration properties of hydroxypropyl methylcellulose matrices containing naproxen and naproxen sodium **200**, 161
Kaufmann, G., see Ikechukwu Ugwoke, M. **202**, 125
Kauppinen, T., see Karhu, M. **196**, 95
Kaur, I.P., M. Singh, M. Kanwar, Formulation and evaluation of ophthalmic preparations of acetazolamide **199**, 119
Kawahara, E., see Fujii, M. **205**, 117
Kawano, K., see Hanawa, T. **210**, 109
Kawasaki, N., see Miyazaki, S. **204**, 127
Kawasaki, Y., see Mizushima, J. **197**, 193
Kawashima, M., see Mizushima, J. **197**, 193
Kayser, O., Nanosuspensions for the formulation of aphidicolin to improve drug targeting effects against *Leishmania* infected macrophages **196**, 253
Kayser, O., see Grau, M.J. **196**, 155
Kayser, O., see Jacobs, C. **196**, 161
Kayser, O., see Krause, K.P. **196**, 169
Keating, S.M., see McCarron, P.A. **193**, 37
Kellaway, I.W., see Birchall, J.C. **197**, 221
Kellaway, I.W., see Jones, B.G. **195**, 17
Kellaway, I.W., see Lee, J. **204**, 137
Kellaway, I.W., see Lee, J. **195**, 35
Kellaway, I.W., see Lee, J. **195**, 29
Kemper, M.S., see Patel, A.D. **206**, 63
Khader, M.A.A., see Billa, N. **201**, 109
Khan, K.A., see Cox, P.J. **193**, 73
Khan, M.A., S.V. Sastry, S.R. Vaithiyalingam, V. Agarwal, S. Nazzal, I.K. Reddy, Captopril gastrointestinal therapeutic system coated with cellulose acetate pseudolatex: evaluation of main effects of several formulation variables **193**, 147
Khanna, M., see Ghosal, S. **194**, 15
Khoo, S.-M., C.J.H. Porter, W.N. Charman, The formulation of Halofantrine as either non-solubilising PEG 6000 or solubilising lipid based solid dispersions: Physical stability and absolute bioavailability assessment **205**, 65
Kiesvaara, J., see Ahola, M. **195**, 219
Kiesvaara, J., see Korhonen, M. **197**, 143
Kiesvaara, J., see Kortesuo, P. **200**, 223
Kilpeläinen, I., see Paavola, A. **199**, 85
Kim, D.-D., see Kim, J.-E. **201**, 29
Kim, E.J., K.S. Han, M.G. Lee, Intestinal first-pass effect of bumetanide in rats **194**, 193
Kim, I.-S., see Ryu, J.-G. **200**, 231
Kim, I.-S., Y.-I. Jeong, C.-S. Cho, S.-H. Kim, Core-shell type polymeric nanoparticles composed of poly(L-lactic acid) and poly(*N*-isopropylacrylamide) **211**, 1
Kim, I.-S., Y.-I. Jeong, C.-S. Cho, S.-H. Kim, Thermo-responsive self-assembled polymeric micelles for drug delivery in vitro **205**, 165
Kim, I.-S., Y.-I. Jeong, S.-H. Kim, Self-assembled hydrogel nanoparticles composed of dextran and poly(ethylene glycol) macromer **205**, 109
Kim, J.-E., S.-R. Kim, S.-H. Lee, C.-H. Lee, D.-D. Kim, The effect of pore formers on the controlled release of cefadroxil from a polyurethane matrix **201**, 29
Kim, J.-H., Y.-J. Cho, H.-K. Choi, Effect of vehicles and pressure sensitive adhesives on the permeation of tacrine across hairless mouse skin **196**, 105
Kim, J.Y., Y.S. Ku, Enhanced absorption of indomethacin after oral or rectal administration of a self-emulsifying system containing indomethacin to rats **194**, 81
Kim, K.H., see Li, L. **199**, 65
Kim, P.-H., see Cui, J.-H. **210**, 51
Kim, S.-H., see Kim, I.-S. **211**, 1
Kim, S.-H., see Kim, I.-S. **205**, 165
Kim, S.-H., see Kim, I.-S. **205**, 109
Kim, S.-H., see Ryu, J.-G. **200**, 231
Kim, S.-R., see Kim, J.-E. **201**, 29
Kinget, R., see Ikechukwu Ugwoke, M. **202**, 125
Kinget, R., see Uchenna Agu, R. **193**, 219
Kinget, R., see Ugwoke, M.I. **205**, 43
Kinget, R., see Van Gelder, J. **205**, 93
Kirsch, L.E., see Joshi, A.B. **203**, 115
Kitano, H., see Yoshihashi, Y. **204**, 1
Kitano, T., see Mizushima, J. **197**, 193
Kiwada, H., see Ishida, T. **205**, 183
Klimeš, J., see Klimešová, V. **207**, 1
Klimešová, V., K. Palát, K. Waisser, J. Klimeš, Combination of molecular modeling and quantitative structure–activity relationship analysis in the study of antimycobacterial activity of pyridine derivatives **207**, 1

Kluczykowska, B., see Jachowicz, R. **206**, 13
Kneuer, C., M. Sameti, E.G. Haltner, T. Schiestel, H. Schirra, H. Schmidt, C.-M. Lehr, Silica nanoparticles modified with aminosilanes as carriers for plasmid DNA **196**, 257
Kobayashi, M., see Fukui, E. **204**, 7
Kobayashi, Y., S. Ito, S. Itai, K. Yamamoto, Physicochemical properties and bioavailability of carbamazepine polymorphs and dihydrate **193**, 137
Kogure, K., T. Itoh, O. Okuda, K. Hayashi, M. Ueno, The delivery of protein into living cells by use of membrane fusible erythrocyte ghosts **210**, 117
Koizumi, T., see Phaechamud, T. **198**, 97
Kojima, H., see Ishida, T. **205**, 183
Korhonen, M., H. Niskanen, J. Kiesvaara, J. Yliruusi, Determination of optimal combination of surfactants in creams using rheology measurements **197**, 143
Kortesuo, P., M. Ahola, M. Kangas, I. Kangasniemi, A. Yli-Urpo, J. Kiesvaara, In vitro evaluation of sol–gel processed spray dried silica gel microspheres as carrier in controlled drug delivery **200**, 223
Kortesuo, P., see Ahola, M. **195**, 219
Kortunay, S., see Öztürk, F. **204**, 97
Kortunay, S., see Öztürk, F. **204**, 91
Kosasih, A., B.J. Bowman, R.J. Wigent, C.M. Ofner, III, Characterization and in vitro release of methotrexate from gelatin/methotrexate conjugates formed using different preparation variables **204**, 81
Koskinen, L.-O.D., see Magnusson, B.M. **195**, 55
Kossen, N.W.F., see Schaafsma, S.H. **193**, 175
Kotsilkova, R., see Michailova, V. **209**, 45
Koumenis, I.L., Z. Shahrokh, S. Leong, V. Hsei, L. Deforge, G. Zapata, Modulating pharmacokinetics of an anti-interleukin-8 $F(ab')_2$ by amine-specific PEGylation with preserved bioactivity **198**, 83
Kranz, H., see Siepmann, J. **201**, 151
Kratzel, M., see Valenta, C. **197**, 77
Krause, K.P., O. Kayser, K. Mäder, R. Gust, R.H. Müller, Heavy metal contamination of nanosuspensions produced by high-pressure homogenisation **196**, 169
Kresse, M., see Seehof, K. **196**, 231
Kreuter, J., see Coester, C. **196**, 147
Kreuter, J., see Weber, C. **196**, 197
Kreuter, J., see Weber, C. **194**, 91
Krishnamurthy, R., J.A. Lumpkin, R. Sridhar, Inactivation of lysozyme by sonication under conditions relevant to microencapsulation **205**, 23
KrishnaPrasad, B.N., see Ghosal, S. **194**, 15
Kristensen, S., see Stensrud, G. **198**, 213
Kristl, J., see Ahlin, P. **196**, 241
Kristl, J., see Baumgartner, S. **195**, 125
Kristl, J., see Gašperlin, M. **196**, 37
Krogars, K., J. Heinämäki, J. Vesalahti, M. Marvola, O. Antikainen, J. Yliruusi, Extrusion–spheronization of pH-sensitive polymeric matrix pellets for possible colonic drug delivery **199**, 187
Krstulović, A.M., see Lee, C.R. **195**, 159
Krusteva, E., see Michailova, V. **209**, 45
Kuhland, U., see Gröning, R. **193**, 57
Ku, H., see Chen, D. **203**, 141
Kuikka, J., see Karhu, M. **196**, 95
Kumar, A., see Ghosal, S. **194**, 15
Kurt, E., see Öztürk, F. **204**, 97
Kurt, E., see Öztürk, F. **204**, 91
Kurup, T.R.R., see Chan, L.W. **195**, 71
Kusai, A., see Kamba, M. **208**, 61
Ku, Y.S., see Kim, J.Y. **194**, 81
Ku, Y.S., see Lee, Y.H. **194**, 221
Kwok, K.Y., R.C. Adami, K.C. Hester, Y. Park, S. Thomas, K.G. Rice, Strategies for maintaining the particle size of peptide DNA condensates following freeze-drying **203**, 81

Lambert, P.A., see Moore, V.A. **210**, 29
Lamprecht, A., N. Ubrich, M. Hombreiro Pérez, C.-M. Lehr, M. Hoffman, P. Maincent, Influences of process parameters on nanoparticle preparation performed by a double emulsion pressure homogenization technique **196**, 177
Lamprecht, A., U.F. Schäfer, C.-M. Lehr, Visualization and quantification of polymer distribution in microcapsules by confocal laser scanning microscopy (CLSM) **196**, 223
Lane, R.A., G. Buckton, The novel combination of dynamic vapour sorption gravimetric analysis and near infra-red spectroscopy as a hyphenated technique **207**, 49
Langer, K., see Coester, C. **196**, 147
Langer, K., see Weber, C. **211**, 67
Langer, K., see Weber, C. **196**, 197
Langer, K., see Weber, C. **194**, 91
Lansley, A.B., see Warisnoicharoen, W. **198**, 7
Lastra, C.F., see Modamio, P. **194**, 249
Latham, R., see Reason, M. **195**, 25
Laugel, C., see Clément, P. **207**, 7
Lawrence, M.J., see Warisnoicharoen, W. **198**, 7
Leclerc, B., see Charlier, A. **200**, 115
Le Corre, P., see Clément, R. **203**, 227
Le Corre, P., see Torché, A.-M. **201**, 15
Lee, B.-J., see Cui, J.-H. **210**, 51
Lee, C.-H., see Kim, J.-E. **201**, 29
Lee, C.R., C. Nguyen van Dau, A.M. Krstulović, Artefact formation in the determination of residual solvents according to a method of the European Pharmacopeia **195**, 159
Lee, J.-H., see Ryu, J.-G. **200**, 231
Lee, J.-H., T.G. Park, H.-K. Choi, Effect of formulation and processing variables on the characteristics of microspheres for water-soluble drugs prepared by w/o/o double emulsion solvent diffusion method **196**, 75
Lee, J., I.W. Kellaway, Buccal permeation of [D-Ala^2, D-Leu^5]enkephalin from liquid crystalline phases of glyceryl monooleate **195**, 35
Lee, J., I.W. Kellaway, Combined effect of oleic acid and polyethylene glycol 200 on buccal permeation of [D-Ala^2, D-Leu^5]enkephalin from a cubic phase of glyceryl monooleate **204**, 137
Lee, J., I.W. Kellaway, In vitro peptide release from liquid crystalline buccal delivery systems **195**, 29
Lee, J.K., see Perkins, W.R. **200**, 27

Lee, M.G., see Kim, E.J. **194**, 193
Lee, S.-H., see Kim, J.-E. **201**, 29
Lee, S.J., M. Rosenberg, Microencapsulation of theophylline in whey proteins: effects of core-to-wall ratio **205**, 147
Lee, Y.H., K.H. Park, Y.S. Ku, Pharmacokinetic changes of cyclosporine after intravenous and oral administration to rats with uranyl nitrate-induced acute renal failure **194**, 221
Lee, Z., M.S. Berridge, W.H. Finlay, D.L. Heald, Mapping PET-measured triamcinolone acetonide (TAA) aerosol distribution into deposition by airway generation **199**, 7
Leffler, C.C., B.W. Müller, Influence of the acid type on the physical and drug liberation properties of chitosan–gelatin sponges **194**, 229
Lehr, C.-M., see Gershanik, T. **211**, 29
Lehr, C.-M., see Kneuer, C. **196**, 257
Lehr, C.-M., see Lamprecht, A. **196**, 177
Lehr, C.-M., see Lamprecht, A. **196**, 223
Lentz, K.A., J. Hayashi, L.J. Lucisano, J.E. Polli, Development of a more rapid, reduced serum culture system for Caco-2 monolayers and application to the biopharmaceutics classification system **200**, 41
Leo, E., F. Forni, M.T. Bernabei, Surface drug removal from ibuprofen-loaded PLA microspheres **196**, 1
Leong, S., see Koumenis, I.L. **198**, 83
Lerk, C.F., see Steendam, R. **204**, 23
Leroux, J.-C., see Ruel-Gariépy, E. **203**, 89
Leung, D.M., see Wu, S.-L. **200**, 1
Le Verge, R., see Clément, R. **203**, 227
Le Verge, R., see Torché, A.-M. **201**, 15
Lévy, M.-C., see Pariot, N. **211**, 19
Liang, J.F., Y.T. Li, V.C. Yang, A novel approach for delivery of enzyme drugs: preliminary demonstration of feasibility and utility in vitro **202**, 11
Liang, W., see Hu, Q. **202**, 121
Li, C.J., see Obata, Y. **198**, 191
Liedtke, S., S. Wissing, R.H. Müller, K. Mäder, Influence of high pressure homogenisation equipment on nanodispersions characteristics **196**, 183
Liesenfeld, O., see Schöler, N. **196**, 235
Lieske, A., see Gessner, A. **196**, 245
Li, L., S. Gorukanti, Y.M. Choi, K.H. Kim, Rapid-onset intranasal delivery of anticonvulsants: pharmacokinetic and pharmacodynamic evaluation in rabbits **199**, 65
Lindberg, M., see Bárány, E. **195**, 189
Lindhardt, K., C. Ravn, S. Gizurarson, E. Bechgaard, Intranasal absorption of buprenorphine — in vivo bioavailability study in sheep **205**, 159
Lin, H.-I., see Chen, D. **203**, 141
Lippacher, A., R.H. Müller, K. Mäder, Investigation on the viscoelastic properties of lipid based colloidal drug carriers **196**, 227
Liu, P., see Anigbogu, A. **200**, 195
Liu, Y., see Ng, K.-y. **193**, 157
Li, X., see Jasti, B.R. **208**, 35
Li, X., see Perkins, W.R. **200**, 27
Li, Y., see Zhang, Q. **200**, 153
Li, Y.T., see Liang, J.F. **202**, 11
Ljunggren, L., N. Volkova, H. Hansson, Calorimetry a method to be used to characterise pyrolytically decarboxylated bicarbonate and assess its stability at elevated humidities **202**, 71
Llabrés, M., A. Oliva, J. Fariña, Statistical assessment of between batch stability equivalence **204**, 61
Llinares, F., see López, A. **202**, 133
Lloyd, A.W., see Soozandehfar, S.H. **198**, 71
Lloyd, P., see Farr, S.J. **198**, 63
Lodén, M., see Bárány, E. **195**, 189
Lopes, A., see Bettencourt, A. **197**, 161
López, A., F. Llinares, C. Cortell, M. Herráez, Comparative enhancer effects of Span®20 with Tween®20 and Azone® on the in vitro percutaneous penetration of compounds with different lipophilicities **202**, 133
López-Carballo, G., see López-Castellano, A. **203**, 245
López-Castellano, A., C. Cortell-Ivars, G. López-Carballo, M. Herráez-Domínguez, The influence of Span®20 on stratum corneum lipids in Langmuir monolayers: comparison with Azone® **203**, 245
López, O., see Cócera, M. **207**, 39
Lopez, R.F.V., J.H. Collett, M.V.L.B. Bentley, Influence of cyclodextrin complexation on the in vitro permeation and skin metabolism of dexamethasone **200**, 127
Lora, S., see Caliceti, P. **211**, 57
Loth, H., G. Hauck, D. Borchert, F. Theobald, Statistical testing of drug accumulation in skin tissues by linear regression versus contents of stratum corneum lipids **209**, 95
Lovrek, M., B. Zorc, B. Boneschans, I. Butula, Macromolecular prodrugs. VIII. Synthesis of polymer–gemfibrozil conjugates **200**, 59
Lucida, H., J.E. Parkin, V.B. Sunderland, Kinetic study of the reaction of sulfamethoxazole and glucose under acidic conditions: I. Effect of pH and temperature **202**, 47
Lucisano, L.J., see Lentz, K.A. **200**, 41
Lukowski, G., J. Kasbohm, P. Pflegel, A. Illing, H. Wulff, Crystallographic investigation of cetylpalmitate solid lipid nanoparticles **196**, 201
Lumpkin, J.A., see Krishnamurthy, R. **205**, 23
Lundberg, B.B., G. Griffiths, H.J. Hansen, Specific binding of sterically stabilized anti-B-cell immunoliposomes and cytotoxicity of entrapped doxorubicin **205**, 101
Luner, P.E., see Patel, A.D. **206**, 63
Lyons, K.C., W.N. Charman, R. Miller, C.J.H. Porter, Factors limiting the oral bioavailability of *N*-acetylglucosaminyl-*N*-acetylmuramyl dipeptide (GMDP) and enhancement of absorption in rats by delivery in a water-in-oil microemulsion **199**, 17

MacAdam, A.B., Z.B. Shafi, C. Marriott, G.P. Martin, S.L. James, Anti-mucus polyclonal antibody production, purification and linkage to the surface of albumin microspheres **195**, 147
Machida, Y., see Yahagi, R. **193**, 205
Machida, Y., see Yahagi, R. **193**, 205
Maciejewska, A., see Jachowicz, R. **206**, 13

Mackeben, S., C.C. Müller-Goymann, Solubilization of timolol maleate in reversed micellar systems: Measurement of particle size using SAXS and PCS **196**, 207
MacManus, S.M., see Cox, P.J. **204**, 133
Madan, S., see Gupta, A.K. **209**, 1
Mäder, K., see Gessner, A. **196**, 245
Mäder, K., see Jenning, V. **205**, 15
Mäder, K., see Katzhendler, I. **200**, 161
Mäder, K., see Krause, K.P. **196**, 169
Mäder, K., see Liedtke, S. **196**, 183
Mäder, K., see Lippacher, A. **196**, 227
Mäder, K., see Seehof, K. **196**, 231
Mäder, K., see Zimmermann, E. **196**, 211
Maffei, P., see Ceschel, G.C. **195**, 171
Maggi, L., R. Bruni, U. Conte, High molecular weight polyethylene oxides (PEOs) as an alternative to HPMC in controlled release dosage forms **195**, 229
Magnusson, B.M., L.-O.D. Koskinen, In vitro percutaneous penetration of topically applied capsaicin in relation to in vivo sensation responses **195**, 55
Mahapatro, M., see Ng, K.-y. **193**, 157
Mahar Doan, K.M., S. Ng, K.M.K. Boje, Cellular transport processes of aminoguanidine, a nitric oxide synthase inhibitor, in the opossum kidney cell culture line **194**, 209
Maia, C.S., W. Mehnert, M. Schäfer-Korting, Solid lipid nanoparticles as drug carriers for topical glucocorticoids **196**, 165
Maibach, H.I., see Mizushima, J. **197**, 193
Maibach, H., see Anigbogu, A. **200**, 195
Maillard-Salin, D.G., P. Bécourt, G. Couarraze, A study of the adhesive–skin interface: correlation between adhesion and passage of a drug **200**, 121
Maillard-Salin, D.G., P. Bécourt, G. Couarraze, Physical evaluation of a new patch made of a progestomimetic in a silicone matrix **199**, 29
Maincent, P., see Lamprecht, A. **196**, 177
Maitani, Y., K. Nakamura, H. Suenaga, K. Kamata, K. Takayama, T. Nagai, The enhancing effect of soybean-derived sterylglucoside and β-sitosterol β-D-glucoside on nasal absorption in rabbits **200**, 17
Maitani, Y., see Junping, W. **203**, 61
Maitra, A., see Gaur, U. **202**, 1
Maitra, A., see Gupta, A.K. **209**, 1
Ma, J.K.A., see Yang, X. **195**, 93
Majumdar, D.K., see Gupta, A.K. **209**, 1
Malamataris, S., see Nikolakakis, I. **201**, 79
Malamataris, S., see Panagopoulou-Kaplani, A. **195**, 239
Malanga, C.J., see Yang, X. **195**, 93
Malinovsky, J.-M., see Clément, R. **203**, 227
Malmsten, M., see Scherlund, M. **211**, 37
Malmsten, M., see Scherlund, M. **194**, 103
Manderioli, A., see Mura, P. **193**, 85
Marchais, H., see Skiba, M. **198**, 1
Marchetti, J.M., see Bentley, M.V.L.B. **193**, 49
Marengo, E., R. Cavalli, O. Caputo, L. Rodriguez, M.R. Gasco, Scale-up of the preparation process of solid lipid nanospheres. Part I **205**, 3
Marichal, C., see Birchall, J.C. **197**, 233
Mariño, E.L., see Modamio, P. **194**, 249
Marriott, C., see MacAdam, A.B. **195**, 147
Marriott, C., see Tee, S.K. **208**, 111
Marriott, C., see Zeng, X.M. **200**, 93
Marshall, K., see DeCrosta, M.T. **198**, 113
Martin, G.P., see MacAdam, A.B. **195**, 147
Martin, G.P., see McDonald, K.J. **201**, 89
Martin, G.P., see Soozandehfar, S.H. **198**, 71
Martin, G.P., see Tee, S.K. **208**, 111
Martin, G.P., see Zeng, X.M. **200**, 93
Martin, G.P., see Zeng, X.M. **197**, 41
Martínez-Pacheco, R., see Alvarez-Lorenzo, C. **197**, 107
Marton, S., see Farkas, E. **193**, 239
Marty, J.-P., see Clément, P. **207**, 7
Maruyama, K., see Moribe, K. **201**, 37
Maruyama, K., see Moribe, K. **193**, 97
Marvola, M., see Krogars, K. **199**, 187
Mason, J., see Washington, N. **198**, 139
Massing, U., see Moog, R. **206**, 43
Masters, G.R., see Perkins, W.R. **200**, 27
Matalka, K., see Albarghouthi, M. **206**, 23
Matarrese, M., see Moresco, R.M. **204**, 101
Matsumoto, M., see Fujii, M. **205**, 117
Matsumoto, M., see Ishikawa, T. **202**, 173
Matsuo, S., see Shimada, K. **203**, 255
Maurin, F., see Séchoy, O. **207**, 109
Mayer, J.M., see Furrer, P. **207**, 89
Mayhew, E., see Perkins, W.R. **200**, 27
McCall, J.W., see Kang, L. **206**, 35
McCarron, P.A., A.D. Woolfson, S.M. Keating, Response surface methodology as a predictive tool for determining the effects of preparation conditions on the physicochemical properties of poly(isobutylcyanoacrylate) nanoparticles **193**, 37
McDonald, K.J., G.P. Martin, Transition to CFC-free metered dose inhalers — into the new millennium **201**, 89
McGinity, J.W., see Repka, M.A. **202**, 63
McKeown, N.B., see Milhem, O.M. **197**, 239
McPhail, D., L. Tetley, C. Dufes, I.F. Uchegbu, Liposomes encapsulating polymeric chitosan based vesicles — a vesicle in vesicle system for drug delivery **200**, 73
Meaney, C.M., C.M. O'Driscoll, A comparison of the permeation enhancement potential of simple bile salt and mixed bile salt:fatty acid micellar systems using the CaCo-2 cell culture model **207**, 21
Mehnert, W., see Maia, C.S. **196**, 165
Mehta, R.C., see Jasti, B.R. **208**, 35
Mehvar, R., see Rensberger, K.L. **207**, 71
Menning, M.M., see Badawy, S.I.F. **198**, 51
Mercadé, M.E., see Cócera, M. **207**, 39
Merclin, N., see Karami, K. **201**, 121
Merino-Sanjuan, M., see Ruiz-Carretero, P. **202**, 89
Merkle, H.P., see Prior, S. **196**, 115
Michael, Y., B.Z. Chowdhry, I.C. Ashurst, M.J. Snowden, C. Davies-Cutting, S. Gray, The physico-chemical properties of salmeterol and fluticasone propionate in different solvent environments **200**, 279

Michailova, V., S. Titeva, R. Kotsilkova, E. Krusteva, E. Minkov, Water uptake and relaxation processes in mixed unlimited swelling hydrogels **209**, 45
Michniak, B.B., see El-Kattan, A.F. **198**, 179
Miglietta, A., R. Cavalli, C. Bocca, L. Gabriel, M. Rosa Gasco, Cellular uptake and cytotoxicity of solid lipid nanospheres (SLN) incorporating doxorubicin or paclitaxel **210**, 61
Milhem, O.M., C. Myles, N.B. McKeown, D. Attwood, A. D'Emanuele, Polyamidoamine Starburst® dendrimers as solubility enhancers **197**, 239
Miller, R., see Lyons, K.C. **199**, 17
Minkov, E., see Michailova, V. **209**, 45
Mishra, V., see Vyas, S.P. **210**, 1
Mitra, A.K., see Chowdhury, D.K. **193**, 113
Mitra, A.K., see Mitra, R. **205**, 127
Mitra, A.K., see Tengamnuay, P. **197**, 53
Mitra, R., I. Pezron, W.A. Chu, A.K. Mitra, Lipid emulsions as vehicles for enhanced nasal delivery of insulin **205**, 127
Miwa, A., T. Yajima, S. Itai, Prediction of suitable amount of water addition for wet granulation **195**, 81
Miyagishima, A., see Shimada, K. **203**, 255
Miyamura, N., see Fukui, E. **204**, 7
Miyazaki, S., N. Kawasaki, T. Nakamura, M. Iwatsu, T. Hayashi, W.-M. Hou, D. Attwood, Oral mucosal bioadhesive tablets of pectin and HPMC: in vitro and in vivo evaluation **204**, 127
Mizushima, J., Y. Kawasaki, T. Tabohashi, T. Kitano, K. Sakamoto, M. Kawashima, R. Cooke, H.I. Maibach, Effect of surfactants on human stratum corneum: electron paramagnetic resonance study **197**, 193
M. Lukas, T., see D. Ticehurst, M. **193**, 247
Mlynek, G.M., L.J. Calvo, J.R. Robinson, Carrier-enhanced human growth hormone absorption across isolated rabbit intestinal tissue **197**, 13
Modamio, P., C.F. Lastra, E.L. Mariño, A comparative in vitro study of percutaneous penetration of β-blockers in human skin **194**, 249
Moës, A.J., see Semdé, R. **197**, 181
Moës, A.J., see Semdé, R. **197**, 169
Molina Díaz, A., see Ayora Cañada, M.J. **202**, 113
Molpeceres, J., M. Chacón, M. Guzmán, M.R. Aberturas, L. Berges, Dependency of cyclosporine tissue distribution and metabolism on the age and gender of rats after a single intravenous dose **197**, 129
Mommaas, M., see Ponec, M. **203**, 211
Moneghini, M., see Voinovich, D. **203**, 235
Monem, A.S., F.M. Ali, M.W. Ismail, Prolonged effect of liposomes encapsulating pilocarpine HCl in normal and glaucomatous rabbits **198**, 29
Monteiro, J., see Bettencourt, A. **197**, 161
Monticone, V., see Cherkaoui, I. **201**, 71
Moog, R., M. Brandl, R. Schubert, C. Unger, U. Massing, Effect of nucleoside analogues and oligonucleotides on hydrolysis of liposomal phospholipids **206**, 43
Moore, V.A., W.J. Irwin, P. Timmins, P.A. Lambert, S. Chong, S.A. Dando, R.A. Morrison, A rapid screening system to determine drug affinities for the intestinal dipeptide transporter 2: affinities of ACE inhibitors **210**, 29
Moore, V.A., W.J. Irwin, P. Timmins, S. Chong, S.A. Dando, R.A. Morrison, A rapid screening system to determine drug affinities for the intestinal dipeptide transporter 1: system characterisation **210**, 15
Moore, W.D., see Wissing, S. **199**, 141
Morana, A., I. Di Lernia, M. Carteni, R. De Rosa, M. De Rosa, Synthesis and characterisation of a new class of stable *S*-adenosyl-L-methionine salts **194**, 61
Moresco, R.M., M. Matarrese, D. Soloviev, P. Simonelli, M. Rigamonti, C. Gobbo, S. Todde, A. Carpinelli, M. Galli Kienle, F. Fazio, Synthesis and in vivo evaluation of [^{11}C]ICI 118551 as a putative subtype selective β_2-adrenergic radioligand **204**, 101
Moretti, M.D.L., see Ceschel, G.C. **195**, 171
Moribe, K., K. Maruyama, M. Iwatsuru, Molecular localization and state of amphotericin B in PEG liposomes **193**, 97
Moribe, K., K. Maruyama, M. Iwatsuru, Spectroscopic investigation of the molecular state of nystatin encapsulated in liposomes **201**, 37
Morishita, M., M. Kajita, A. Suzuki, K. Takayama, Y. Chiba, S. Tokiwa, T. Nagai, The dose-related hypoglycemic effects of insulin emulsions incorporating highly purified EPA and DHA **201**, 175
Morishita, M., see Onuki, Y. **198**, 147
Morrison, R.A., see Moore, V.A. **210**, 15
Morrison, R.A., see Moore, V.A. **210**, 29
Mostafavi, S.A., R.T. Foster, Pharmacokinetics of metoprolol enantiomers following single and multiple administration of racemate in rat **202**, 97
Mountfield, R.J., see Bittner, B. **205**, 195
Mountfield, R.J., S. Senepin, M. Schleimer, I. Walter, B. Bittner, Potential inhibitory effects of formulation ingredients on intestinal cytochrome P450 **211**, 89
Movileanu, L., I. Neagoe, M.L. Flonta, Interaction of the antioxidant flavonoid quercetin with planar lipid bilayers **205**, 135
Moyer, K.L., see Ravivarapu, H.B. **194**, 181
Mørck Nielsen, H., M. Rømer Rassing, TR146 cells grown on filters as a model of human buccal epithelium: V. Enzyme activity of the TR146 cell culture model, human buccal epithelium and porcine buccal epithelium, and permeability of leu-enkephalin **200**, 261
Mulder, A., see Ponec, M. **203**, 211
Müller, B.W., see Leffler, C.C. **194**, 229
Müller, D.G., see Beetge, E. **193**, 261
Müller-Goymann, C.C., see Mackeben, S. **196**, 207
Müller-Goymann, C.C., see Schmid, S. **197**, 35
Müller-Goymann, C.C., see Schneeweis, A. **196**, 193
Müller, R.H., see Gessner, A. **196**, 245
Müller, R.H., see Grau, M.J. **196**, 155
Müller, R.H., see Jacobs, C. **196**, 161
Müller, R.H., see Krause, K.P. **196**, 169
Müller, R.H., see Liedtke, S. **196**, 183
Müller, R.H., see Lippacher, A. **196**, 227
Müller, R.H., see Schöler, N. **196**, 235

Müller, R.H., see Seehof, K. **196**, 231
Müller, R.H., see Zimmermann, E. **196**, 211
Munday, D.L., P.J. Cox, Compressed xanthan and karaya gum matrices: hydration, erosion and drug release mechanisms **203**, 179
Munday, D.L., see Cox, P.J. **193**, 73
Muñiz, E., see Blanco, M.D. **202**, 29
Muñoz-Ruiz, A., see Ferrero, C. **202**, 21
Muramatsu, E., see Hanawa, T. **210**, 109
Muramatsu, M., K. Kanada, A. Nishida, K. Ouchi, N. Saito, M. Yoshida, A. Shimoaka, T. Ozeki, H. Yuasa, Y. Kanaya, Application of Carbopol® to controlled release preparations I. Carbopol® as a novel coating material **199**, 77
Mura, P., M.T. Faucci, A. Manderioli, G. Bramanti, Influence of the preparation method on the physicochemical properties of binary systems of econazole with cyclodextrins **193**, 85
Murdan, S., *Percutaneous Absorption, Drugs — Cosmetics — Mechanisms — Methodology, 3rd Edition*, Edited by R.L. Bronaugh and H.I. Maibach, Marcel Dekker Inc., New York, 1999. ISBN 0-82471966-2; 955 pages **210**, 121
Muthaiah, A., see Chan, L.W. **195**, 71
Myles, C., see Milhem, O.M. **197**, 239

Nacher, A., see Ruiz-Carretero, P. **202**, 89
Nagai, T., see Junping, W. **203**, 61
Nagai, T., see Maitani, Y. **200**, 17
Nagai, T., see Morishita, M. **201**, 175
Nagai, T., see Obata, Y. **198**, 191
Nagai, T., see Onuki, Y. **198**, 147
Nagai, T., see Zhang, Q. **200**, 153
Nah, J.-W., see Jeon, H.-J. **207**, 99
Nah, J.-W., see Ryu, J.-G. **200**, 231
Nakajima, S., see Hanawa, T. **210**, 109
Nakamura, K., see Maitani, Y. **200**, 17
Nakamura, T., see Miyazaki, S. **204**, 127
Nannipieri, E., see Carelli, V. **202**, 103
Nazzal, S., see Khan, M.A. **193**, 147
Neagoe, I., see Movileanu, L. **205**, 135
Neau, S.H., M.Y. Chow, G.A. Hileman, M.J. Durrani, F. Gheyas, B.A. Evans, Formulation and process considerations for beads containing Carbopol® 974P, NF resin made by extrusion-spheronization **199**, 129
Németh, Z., see Farkas, E. **193**, 239
Neubert, R.H.H., see Duc Hanh, B. **204**, 145
Neubert, R.H.H., see Duc Hanh, B. **204**, 151
Neuhuber, W., see Welz, C. **196**, 251
Newman, S.P., I.R. Wilding, P.H. Hirst, Human lung deposition data: the bridge between in vitro and clinical evaluations for inhaled drug products? **208**, 49
Newton, J.M., F. Podczeck, **198**, 249
Ng, K.-y., L. Zhao, Y. Liu, M. Mahapatro, The effects of polyethyleneglycol (PEG)-derived lipid on the activity of target-sensitive immunoliposome **193**, 157
Ng, S., see Mahar Doan, K.M. **194**, 209
Nguyen, J., see Perkins, W.R. **200**, 27
Nguyen van Dau, C., see Lee, C.R. **195**, 159
Nichols, G., see D. Ticehurst, M. **193**, 247
Nielsen, H.M., M.R. Rassing, TR146 cells grown on filters as a model of human buccal epithelium: IV. Permeability of water, mannitol, testosterone and β-adrenoceptor antagonists. Comparison to human, monkey and porcine buccal mucosa **194**, 155
Nielsen, H.W., E. Bechgaard, B. Twile, E. Didriksen, H. Sørensen, Intranasal administration of different liquid formulations of bumetanide to rabbits **204**, 35
Niklasson, G.A., see Hedenus, P. **202**, 141
Niklasson, G.A., see Strømme Mattsson, M. **199**, 179
Nikolakakis, I., K. Kachrimanis, S. Malamataris, Relations between crystallisation conditions and micromeritic properties of ibuprofen **201**, 79
Nishida, A., see Muramatsu, M. **199**, 77
Nishimura, K., see Kamba, M. **208**, 61
Niskanen, H., see Korhonen, M. **197**, 143
Noor, A.M., see Julianto, T. **200**, 53
Nozawa, Y., see Shimada, K. **203**, 255
Nuijen, B., M. Bouma, R.E.C. Henrar, U. Brauns, P. Bette, A. Bult, J.H. Beijnen, In vitro biocompatibility studies with the experimental anticancer agent BIBX1382BS **194**, 261
Nur, A.O., J.S. Zhang, Recent progress in sustained/controlled oral delivery of captopril: an overview **194**, 139
Nürnberg, E., see Jachowicz, R. **206**, 13
Nyqvist, H., see Crowley, K.J. **211**, 9
Nyqvist, H., see Emås, M. **197**, 117

Obata, Y., H. Sato, C.J. Li, K. Takayama, K. Higashiyama, T. Nagai, K. Isowa, Effect of synthesized cyclohexanol derivatives using L-menthol as a lead compound on the percutaneous absorption of ketoprofen **198**, 191
O'Driscoll, C.M., see Meaney, C.M. **207**, 21
Ofner, C.M., III, see Kosasih, A. **204**, 81
Oh, I.-J., see Shin, S.-C. **193**, 213
Okikawa, J.K., see Farr, S.J. **198**, 63
Okuda, O., see Kogure, K. **210**, 117
Oliva, A., see Llabrés, M. **204**, 61
Olmo, R., see Blanco, M.D. **202**, 29
Omar, A., see Billa, N. **201**, 109
Onishi, H., see Yahagi, R. **193**, 205
Onuki, Y., M. Morishita, K. Takayama, S. Tokiwa, Y. Chiba, K. Isowa, T. Nagai, In vivo effects of highly purified docosahexaenoic acid on rectal insulin absorption **198**, 147
Ooi, M., see Yuasa, H. **203**, 203
Ouchi, K., see Muramatsu, M. **199**, 77
Owusu-Ababio, G., see Ebube, N.K. **196**, 27
Ozeki, T., see Kasai, T. **204**, 53
Ozeki, T., see Muramatsu, M. **199**, 77
Ozeki, T., see Yuasa, H. **209**, 69
Öztürk, F., E. Kurt, Ü. İnan, S. Kortunay, S.S. İlker, N.E. Başcı, A. Bozkurt, Penetration of topical and oral ofloxacin into the aqueous and vitreous humor of inflamed rabbit eyes **204**, 91
Öztürk, F., E. Kurt, Ü. İnan, S. Kortunay, S.S. İlker, N.E. Başcı, A. Bozkurt, The effects of prolonged acute use and inflammation on the ocular penetration of topical ciprofloxacin **204**, 97

Paavola, A., I. Kilpeläinen, J. Yliruusi, P. Rosenberg, Controlled release injectable liposomal gel of ibuprofen for epidural analgesia **199**, 85
Palát, K., see Klimešová, V. **207**, 1
Pálinkás, J., see Farkas, E. **193**, 239
Paliwa, J.K., A.K. Dwivedi, S. Singh, R.C. Gutpa, Pharmacokinetics and in-situ absorption studies of a new anti-allergic compound 73/602 in rats **197**, 213
Palmieri Filippo, G., see Di Martino, P. **197**, 95
Panagopoulou-Kaplani, A., S. Malamataris, Preparation and characterisation of a new insoluble polymorphic form of glibenclamide **195**, 239
Panchagnula, R., N.S. Thomas, Biopharmaceutics and pharmacokinetics in drug research **201**, 131
Panchagnula, R., see Jain, A.K. **206**, 1
Pandhal, K.H., see Zeng, X.M. **197**, 41
Paolino, D., see Saija, A. **199**, 39
Pariot, N., F. Edwards-Lévy, M.-C. Andry, M.-C. Lévy, Cross-linked β-cyclodextrin microcapsules: preparation and properties **211**, 19
Park, E.-S., S.-Y. Chang, M. Hahn, S.-C. Chi, Enhancing effect of polyoxyethylene alkyl ethers on the skin permeation of ibuprofen **209**, 109
Parkin, J.E., see Lucida, H. **202**, 47
Parkin, J.E., see Tan, M. **208**, 23
Park, K.H., see Lee, Y.H. **194**, 221
Park, T.G., see Choi, S.H. **203**, 193
Park, T.G., see Lee, J.-H. **196**, 75
Park, Y.-H., see Jeon, H.-J. **207**, 99
Park, Y., see Kwok, K.Y. **203**, 81
Parra, J.L., see Cócera, M. **207**, 39
Pascual Reguera, M.I., see Ayora Cañada, M.J. **202**, 113
Patel, A.D., P.E. Luner, M.S. Kemper, Quantitative analysis of polymorphs in binary and multi-component powder mixtures by near-infrared reflectance spectroscopy **206**, 63
Patel, D., J.R. Smith, A.W. Smith, N. Grist, P. Barnett, J.D. Smart, An atomic force microscopy investigation of bioadhesive polymer adsorption onto human buccal cells **200**, 271
Patel, G.B., B.J. Agnew, L. Deschatelets, L.P. Fleming, G.D. Sprott, In vitro assessment of archaeosome stability for developing oral delivery systems **194**, 39
Patil, S., see Anigbogu, A. **200**, 195
Paulke, B.-R., see Gessner, A. **196**, 245
Pauwels, R., see Borgström, L. **193**, 227
Pavanetto, F., see Perugini, P. **196**, 51
Peana, A.T., see Ceschel, G.C. **195**, 171
Pečar, S., see Ahlin, P. **196**, 241
Pedraz, J.L., see San Vicente, A. **208**, 13
Peiponen, K.-E., see Silvennoinen, R. **199**, 205
Peksoy, İ., see Tunçay, M. **195**, 179
Pellett, M.A., J. Hadgraft, M.S. Roberts, The back diffusion of glucose across human skin in vitro **193**, 27
Peña, M.A., see Bustamante, P. **194**, 117
Penninckx, F., see Van Gelder, J. **205**, 93
Peppas, N.A., see Siepmann, J. **201**, 151
Pereira, L., see Bettencourt, A. **197**, 161
Pereira, V.M.W., see Santos-Magalhães, N.S. **208**, 71
Perissutti, B., see Voinovich, D. **203**, 235
Perkins, A.C., see Jackson, S.J. **205**, 173
Perkins, W.R., I. Ahmad, X. Li, D.J. Hirsh, G.R. Masters, C.J. Fecko, J.K. Lee, S. Ali, J. Nguyen, J. Schupsky, C. Herbert, A.S. Janoff, E. Mayhew, Novel therapeutic nanoparticles (lipocores): trapping poorly water soluble compounds **200**, 27
Perrone, R.K., see Gandhi, R.B. **201**, 221
Perugini, P., I. Genta, F. Pavanetto, B. Conti, S. Scalia, A. Baruffini, Study on glycolic acid delivery by liposomes and microspheres **196**, 51
Pezron, I., see Mitra, R. **205**, 127
Pflegel, P., see Lukowski, G. **196**, 201
Phaechamud, T., T. Koizumi, G.C. Ritthidej, Chitosan citrate as film former: compatibility with water-soluble anionic dyes and drug dissolution from coated tablet **198**, 97
Pieszczek, B., see Jachowicz, R. **206**, 13
Pietzyk, B., K. Henschke, Degradation of phosphatidylcholine in liposomes containing carboplatin in dependence on composition and storage conditions **196**, 215
Pillai, G.K., M.L.D. Salim, Enhanced inhibition of platelet aggregation in-vitro by niosome-encapsulated indomethacin **193**, 123
Pineda, E.A.G., see Uesu, N.Y. **206**, 85
Ping, Q., see Guo, J. **194**, 201
Ping, Q., see Hu, Q. **202**, 121
Pišek, R., see Planinšek, O. **207**, 77
Pitt, K., see Washington, N. **198**, 139
Plaizier-Vercammen, J., see Brisaert, M. **199**, 49
Plaizier-Vercammen, J., see Brisaert, M. **197**, 153
Planinšek, O., R. Pišek, A. Trojak, S. Srčič, The utilization of surface free-energy parameters for the selection of a suitable binder in fluidized bed granulation **207**, 77
Planinšek, O., see Solmajer, T. **199**, 59
Plazonnet, B., see Furrer, P. **207**, 89
Plessis, J., see Hadgraft, J. **207**, 31
Podczeck, F., see Newton, J.M. **198**, 249
Poli, B., see Carelli, V. **202**, 103
Pollak, P.T., see Yeung, P.K.F. **204**, 17
Polli, J.E., see Lentz, K.A. **200**, 41
Ponec, M., E. Boelsma, A. Weerheim, A. Mulder, J. Bouwstra, M. Mommaas, Lipid and ultrastructural characterization of reconstructed skin models **203**, 211
Pontes, A., see Santos-Magalhães, N.S. **208**, 71
Porter, C.J.H., see Khoo, S.-M. **205**, 65
Porter, C.J.H., see Lyons, K.C. **199**, 17
Prankerd, R.J., **199**, 111
Prestidge, C.A., G. Tsatouhas, Wettability studies of morphine sulfate powders **198**, 201
Primault, R., see Torché, A.-M. **201**, 15
Prior, S., C. Gamazo, J.M. Irache, H.P. Merkle, B. Gander, Gentamicin encapsulation in PLA/PLGA microspheres in view of treating *Brucella* infections **196**, 115
Pritchard, J., see Zeng, X.M. **200**, 93
Pugh, W.J., I.T. Degim, J. Hadgraft, Epidermal permeability–penetrant structure relationships: 4, QSAR of permeant diffusion across human stratum corneum in terms of molecular weight, H-bonding and electronic charge **197**, 203

Raatikainen, P., see Silvennoinen, R. **199**, 205
Rácz, I., see Farkas, E. **193**, 239
Rades, T., see Alany, R.G. **196**, 141
Rades, T., see Copland, M.J. **196**, 135
Rades, T., see de Smidt, P.C. **196**, 187
Radomska, A., R. Dobrucki, The use of some ingredients for microemulsion preparation containing retinol and its esters **196**, 131
Raghavan, S.L., A. Trividic, A.F. Davis, J. Hadgraft, Effect of cellulose polymers on supersaturation and in vitro membrane transport of hydrocortisone acetate **193**, 231
Raghavan, S.L., see Iervolino, M. **198**, 229
Rajabi-Siahboomi, A.R., see Garekani, H.A. **208**, 101
Rajabi-Siahboomi, A.R., see Garekani, H.A. **208**, 87
Ramarao, P., see Kanikkannan, N. **197**, 69
Ramsay, E., J. Hadgraft, J. Birchall, M. Gumbleton, Examination of the biophysical interaction between plasmid DNA and the polycations, polylysine and polyornithine, as a basis for their differential gene transfection in-vitro **210**, 97
Ramsden, J., see Reason, M. **195**, 25
Rascher, W., see Welz, C. **196**, 251
Rassing, M.R., see Nielsen, H.M. **194**, 155
Ravivarapu, H.B., K.L. Moyer, R.L. Dunn, Parameters affecting the efficacy of a sustained release polymeric implant of leuprolide **194**, 181
Ravn, C., see Lindhardt, K. **205**, 159
Rawlins, D.A., see Washington, N. **198**, 139
Reason, M., G. Smith, R. Latham, P. Teesdale-Spittle, J. Ramsden, B. Henry, Characterisation of fatty acid multilayers using a TSM biosensor **195**, 25
Reddy, I.K., see Khan, M.A. **193**, 147
Reiss, S., see Weber, C. **211**, 67
Remon, J.P., see De Brabander, C. **208**, 81
Remon, J.P., see De Brabander, C. **199**, 195
Rensberger, K.L., D.A. Hoganson, R. Mehvar, Dextran-methylprednisolone succinate as a prodrug of methylprednisolone: in vitro immunosuppressive effects on rat blood and spleen lymphocytes **207**, 71
Repka, M.A., J.W. McGinity, Influence of Vitamin E TPGS on the properties of hydrophilic films produced by hot-melt extrusion **202**, 63
Repp, R., see Welz, C. **196**, 251
Rhodes, D.G., see Hu, C. **206**, 109
Ricardo, N., see Bentley, M.V.L.B. **193**, 49
Rice, K.G., see Kwok, K.Y. **203**, 81
Richardson, C., see Allender, C.J. **195**, 39
Richardson, L.A., see Engel, G.L. **198**, 239
Rico, J.M.T., see Bettencourt, A. **197**, 161
Rigamonti, M., see Moresco, R.M. **204**, 101
Riley, T., see Govender, T. **199**, 95
Ritthidej, G.C., see Phaechamud, T. **198**, 97
Rømer Rassing, M., see Mørck Nielsen, H. **200**, 261
Roberts, M.S., see Pellett, M.A. **193**, 27
Roberts, W.J., see Sloan, K.B. **205**, 53
Robinson, J.R., see Mlynek, G.M. **197**, 13
Robson, H., D.Q.M. Craig, D. Deutsch, An investigation into the release of cefuroxime axetil from taste-masked stearic acid microspheres. III. The use of DSC and HSDSC as means of characterising the interaction of the microspheres with buffered media **201**, 211
Robson, H., D.Q.M. Craig, D. Deutsch, An investigation into the release of cefuroxime axetil from taste-masked stearic acid microspheres. II. The effects of buffer composition on drug release **195**, 137
Rodriguez, J.L., see Gutiérrez de Rubalcava, C. **203**, 99
Rodriguez, L., see Marengo, E. **205**, 3
Rojanasakul, Y., see Dokka, S. **206**, 97
Rojanasakul, Y., see Yang, X. **195**, 93
Rosa Gasco, M., see Miglietta, A. **210**, 61
Rosenberg, M., see Lee, S.J. **205**, 147
Rosenberg, P., see Paavola, A. **199**, 85
Rossi, S., see Bonferoni, M.C. **200**, 207
Rouchotas, C., O.E. Cassidy, G. Rowley, Comparison of surface modification and solid dispersion techniques for drug dissolution **195**, 1
Rough, S.L., J. Bridgwater, D.I. Wilson, Effects of liquid phase migration on extrusion of microcrystalline cellulose pastes **204**, 117
Rowe, A.M., see Farr, S.J. **198**, 63
Rowley, G., see Eilbeck, J. **195**, 7
Rowley, G., see Rouchotas, C. **195**, 1
Rubinstein, A., see Baluom, M. **193**, 265
Rubinstein, M.H., see Garekani, H.A. **208**, 101
Rubinstein, M.H., see Garekani, H.A. **208**, 87
Rubsamen, R.M., see Farr, S.J. **198**, 63
Rudd, D.R., see Whitaker, M. **205**, 79
Ruel-Gariépy, E., A. Chenite, C. Chaput, S. Guirguis, J.-C. Leroux, Characterization of thermosensitive chitosan gels for the sustained delivery of drugs **203**, 89
Ruiz-Carretero, P., A. Nacher, M. Merino-Sanjuan, V.G. Casabo, Pharmacokinetics and absolute bioavailability of oral cefuroxime axetil in the rat **202**, 89
Rus, E., see Joshi, A.B. **203**, 115
Ryu, J.-G., Y.-I. Jeong, I.-S. Kim, J.-H. Lee, J.-W. Nah, S.-H. Kim, Clonazepam release from core-shell type nanoparticles of poly(ε-caprolactone)/poly(ethylene glycol)/poly(ε-caprolactone) triblock copolymers **200**, 231

Sa, B., see Tamilvanan, S. **201**, 187
Sadzuka, Y., see Shimada, K. **203**, 255
Sahamethapat, A., see Tengamnuay, P. **197**, 53
Sah, H., Ethyl formate — alternative dispersed solvent useful in preparing PLGA microspheres **195**, 103
Sahoo, S.K., see Gaur, U. **202**, 1
Saija, A., A. Tomaino, D. Trombetta, A. De Pasquale, N. Uccella, T. Barbuzzi, D. Paolino, F. Bonina, In vitro and in vivo evaluation of caffeic and ferulic acids as topical photoprotective agents **199**, 39
Sailasuta, A., see Tengamnuay, P. **197**, 53
Saito, N., see Muramatsu, M. **199**, 77
Sakamoto, K., see Mizushima, J. **197**, 193
Sakr, A., see Cammarn, S.R. **201**, 199
Sakthivel, T., see Shah, D.S. **208**, 41
Saleem, M., see Albarghouthi, M. **206**, 23

Salim, M.L.D., see Pillai, G.K. **193**, 123
Sameti, M., see Kneuer, C. **196**, 257
Sande, S.A., see Stensrud, G. **198**, 213
Sante, M., see Di Martino, P. **197**, 95
Santos-Magalhães, N.S., A. Pontes, V.M.W. Pereira, M.N.P. Caetano, Colloidal carriers for benzathine penicillin G: Nanoemulsions and nanocapsules **208**, 71
San Vicente, A., R.M. Hernández, A.R. Gascón, M.B. Calvo, J.L. Pedraz, Effect of aging on the release of salbutamol sulfate from lipid matrices **208**, 13
Sargon, M.F., see Şenel, S. **193**, 197
Sastry, S.V., see Khan, M.A. **193**, 147
Sathyan, G., S. Hwang, S.K. Gupta, Effect of dosing time on the total intestinal transit time of non-disintegrating systems **204**, 47
Sato, H., see Obata, Y. **198**, 191
Scalia, S., see Perugini, P. **196**, 51
Schaafsma, S.H., P. Vonk, N.W.F. Kossen, Fluid bed agglomeration with a narrow droplet size distribution **193**, 175
Schäfer-Korting, M., see Maia, C.S. **196**, 165
Schäfer, U.F., see Lamprecht, A. **196**, 223
Schapoval, E.E.S., see Cardoso, S.G. **203**, 109
Scherlund, M., A. Brodin, M. Malmsten, Micellization and gelation in block copolymer systems containing local anesthetics **211**, 37
Scherlund, M., M. Malmsten, P. Holmqvist, A. Brodin, Thermosetting microemulsions and mixed micellar solutions as drug delivery systems for periodontal anesthesia **194**, 103
Schiestel, T., see Kneuer, C. **196**, 257
Schirra, H., see Kneuer, C. **196**, 257
Schleimer, M., see Mountfield, R.J. **211**, 89
Schmid, S., C.C. Müller-Goymann, P.C. Schmidt, Interactions during aqueous film coating of ibuprofen with Aquacoat ECD **197**, 35
Schmidt, H., see Kneuer, C. **196**, 257
Schmidt, J.M., see Feher, M. **201**, 239
Schmidt, P.C., see Schmid, S. **197**, 35
Schneeweis, A., C.C. Müller-Goymann, Controlled release of solid-reversed-micellar-solution (SRMS) suppositories containing metoclopramide-HCl **196**, 193
Schöler, N., E. Zimmermann, U. Katzfey, H. Hahn, R.H. Müller, O. Liesenfeld, Preserved solid lipid nanoparticles (SLN) at low concentrations do cause neither direct nor indirect cytotoxic effects in peritoneal macrophages **196**, 235
Schreier, H., see Welz, C. **196**, 251
Schubert, R., see Moog, R. **206**, 43
Schupsky, J., see Perkins, W.R. **200**, 27
Schuster, J.A., see Farr, S.J. **198**, 63
Schwartz, J.B., see DeCrosta, M.T. **198**, 113
Sciot, R., see Ugwoke, M.I. **205**, 43
Sébastian, C., see Séchoy, O. **207**, 109
Séchoy, O., G. Tissié, C. Sébastian, F. Maurin, J.-Y. Driot, C. Trinquand, A new long acting ophthalmic formulation of Carteolol containing alginic acid **207**, 109
Seehof, K., M. Kresse, K. Mäder, R.H. Müller, Interactions of nanoparticles with body proteins — improvement of 2D-PAGE-analysis by internal standard **196**, 231
Seijo, B., see Gutiérrez de Rubalcava, C. **203**, 99
Seki, T., see Hanawa, T. **210**, 109
Semdé, R., K. Amighi, M.J. Devleeschouwer, A.J. Moës, Effect of pectinolytic enzymes on the theophylline release from pellets coated with water insoluble polymers containing pectin HM or calcium pectinate **197**, 169
Semdé, R., K. Amighi, M.J. Devleeschouwer, A.J. Moës, Studies of pectin HM/Eudragit® RL/Eudragit® NE film-coating formulations intended for colonic drug delivery **197**, 181
Şenel, S., G. İkinci, S. Kaş, A. Yousefi-Rad, M.F. Sargon, A.A. Hıncal, Chitosan films and hydrogels of chlorhexidine gluconate for oral mucosal delivery **193**, 197
Senepin, S., see Mountfield, R.J. **211**, 89
Şen, M., C. Uzun, O. Güven, Controlled release of terbinafine hydrochloride from pH sensitive poly(acrylamide/maleic acid) hydrogels **203**, 149
Šentjurc, M., see Ahlin, P. **196**, 241
Serafimovich, S., see Sintov, A. **194**, 125
Serafini, M.F., see Carelli, V. **202**, 103
Seta, Y., see Kamba, M. **208**, 61
Seville, P.C., C. Simons, G. Taylor, P.A. Dickinson, Prodrug to probe solution HFA pMDI formulation and pulmonary esterase activity **195**, 13
Shafiee, M., see Van Gelder, J. **205**, 93
Shafi, Z.B., see MacAdam, A.B. **195**, 147
Shah, D.S., T. Sakthivel, I. Toth, A.T. Florence, A.F. Wilderspin, DNA transfection and transfected cell viability using amphipathic asymmetric dendrimers **208**, 41
Shahrokh, Z., see Koumenis, I.L. **198**, 83
Shantha, K.L., D.R.K. Harding, Preparation and in-vitro evaluation of poly[*N*-vinyl-2-pyrrolidone-polyethylene glycol diacrylate]-chitosan interpolymeric pH-responsive hydrogels for oral drug delivery **207**, 65
Shen, W.-C., see Wang, J. **204**, 111
Shimada, K., S. Matsuo, Y. Sadzuka, A. Miyagishima, Y. Nozawa, S. Hirota, T. Sonobe, Determination of incorporated amounts of poly(ethylene glycol)-derivatized lipids in liposomes for the physicochemical characterization of stealth liposomes **203**, 255
Shimoaka, A., see Muramatsu, M. **199**, 77
Shin, S.-C., C.-W. Cho, I.-J. Oh, Enhanced efficacy by percutaneous absorption of piroxicam from the poloxamer gel in rats **193**, 213
Shin, S.-C., J.-P. Bum, J.-S. Choi, Enhanced bioavailability by buccal administration of triamcinolone acetonide from the bioadhesive gels in rabbits **209**, 37
Shiozawa, K., see Fujii, M. **205**, 117
Shi, X., see Dokka, S. **206**, 97
Shu, X.Z., K.J. Zhu, A novel approach to prepare tripolyphosphate/chitosan complex beads for controlled release drug delivery **201**, 51
Siepmann, J., H. Kranz, N.A. Peppas, R. Bodmeier, Calculation of the required size and shape of hydroxypropyl methylcellulose matrices to achieve desired drug release profiles **201**, 151

Sihorkar, V., see Vyas, S.P. **210**, 1
Silvennoinen, R., V. Hyvärinen, P. Raatikainen, K.-E. Peiponen, Dynamic laser speckle pattern in monitoring of local deformation of tablet surface after compression **199**, 205
Siman, U., see Valenta, C. **197**, 77
Simonelli, P., see Moresco, R.M. **204**, 101
Simons, C., see Seville, P.C. **195**, 13
Singh, B., N. Ahuja, *Pharmaceutical Experimental Design* (*Drugs and the Pharmaceutical Sciences, Vol.* 92), Edited by G.A. Lewis, D. Mathieu and R. Phan-Tan-Luu, 1st Edition, Marcel Dekker, New York, 1999. vi + 498 pp., 23.5 × 15.5 cm., 1.9 lb., Hardcover, ISBN 0-8247-9860-0, Price $175.00 **195**, 247
Singh, J., see Bi, M. **197**, 87
Singh, J., see Kanikkannan, N. **197**, 69
Singh, M., see Kaur, I.P. **199**, 119
Singh, P., see Anigbogu, A. **200**, 195
Singh, S.K., see Suurkuusk, M. **194**, 21
Singh, S., see Ghosal, S. **194**, 15
Singh, S., see Paliwa, J.K. **197**, 213
Sintov, A., S. Serafimovich, A. Gilhar, New topical antiandrogenic formulations can stimulate hair growth in human bald scalp grafted onto mice **194**, 125
Sjöström, B., see Fatouros, A. **194**, 69
Skiba-Lahiani, M., see Skiba, M. **198**, 1
Skiba, M., M. Skiba-Lahiani, H. Marchais, R. Duclos, P. Arnaud, Stability assessment of ketoconazole in aqueous formulations **198**, 1
Sloan, K.B., S.A. DellaVecchia, J.V. Estes, W.J. Roberts, 7-alkylcarbonyl and 7-alkyloxycarbonyl prodrugs of theophylline **205**, 53
Smart, J.D., see Patel, D. **200**, 271
Šmid-Korbar, J., see Gašperlin, M. **196**, 37
Smistad, G., see Stensrud, G. **198**, 213
Smith, A.W., see Patel, D. **200**, 271
Smith, D., see D. Ticehurst, M. **193**, 247
Smith, G.J., see Yeung, P.K.F. **204**, 17
Smith, G., see Reason, M. **195**, 25
Smith, J.C., W.J. Irwin, Ionisation and the effect of absorption enhancers on transport of salicylic acid through silastic rubber and human skin **210**, 69
Smith, J.R., see Patel, D. **200**, 271
Snowden, M.J., see Michael, Y. **200**, 279
Söderberg, I., see Bjerregaard, S. **193**, 1
Solmajer, T., O. Planinšek, S. Srčič, Conformational analysis of 7-oxoacyl-L-alanyl-D-isoglutamines **199**, 59
Soloviev, D., see Moresco, R.M. **204**, 101
Some, I.T., P. Bogaerts, R. Hanus, M. Hanocq, J. Dubois, Improved kinetic parameter estimation in pH-profile data treatment **198**, 39
Sonnergaard, J.M., A critical evaluation of the Heckel equation **193**, 63
Sonobe, T., see Shimada, K. **203**, 255
Soozandehfar, S.H., J.L. Bragger, G.P. Martin, A.W. Lloyd, Synthesis and bacterial degradation of an azopolymer **198**, 71
Sourial, E., see Feher, M. **201**, 239
Souto, C., see Alvarez-Lorenzo, C. **197**, 107
Sparrow, R.A., see Dobson, C.L. **195**, 63
Sprott, G.D., see Patel, G.B. **194**, 39
Srčič, S., see Planinšek, O. **207**, 77
Srčič, S., see Solmajer, T. **199**, 59
Sørensen, H., see Nielsen, H.W. **204**, 35
Sridhar, R., see Krishnamurthy, R. **205**, 23
Staniforth, J.N., see Edge, S. **200**, 67
Stankova, I., see Zhivkova, Z. **200**, 181
Steele, D.F., see Edge, S. **200**, 67
Steele, R.J.C., see Washington, N. **198**, 139
Steendam, R., A.C.E. Eissens, H.W. Frijlink, C.F. Lerk, Plasticisation of amylodextrin by moisture: Consequences for drug release from tablets **204**, 23
Steininger, S., see Bernkop-Schnürch, A. **194**, 239
Stensrud, G., S.A. Sande, S. Kristensen, G. Smistad, Formulation and characterisation of primaquine loaded liposomes prepared by a pH gradient using experimental design **198**, 213
Stephenson, G.A., B.A. Diseroad, Structural relationship and desolvation behavior of cromolyn, cefazolin and fenoprofen sodium hydrates **198**, 167
Stolnik, S., see Govender, T. **199**, 95
Štrancar, J., see Ahlin, P. **196**, 241
Strømme Mattsson, M., P. Hedenus, G.A. Niklasson, R. Ek, A new method of characterising liquid uptake within particles over short time periods **199**, 179
Strømme Mattsson, M., see Hedenus, P. **202**, 141
Suenaga, H., see Maitani, Y. **200**, 17
Sujja-areevath, J., see Cox, P.J. **193**, 73
Sunderland, V.B., see Lucida, H. **202**, 47
Sun, G., see Guo, J. **194**, 201
Suurkuusk, M., S.K. Singh, Formation of HDL-like complexes from apolipoprotein A-I_M and DMPC **194**, 21
Suzuki, A., see Morishita, M. **201**, 175
Suzuki, M., see Hanawa, T. **210**, 109
Sznitowska, M., K. Zurowska-Pryczkowska, E. Dabrowska, S. Janicki, Increased partitioning of pilocarpine to the oily phase of submicron emulsion does not result in improved ocular bioavailability **202**, 161

Tabohashi, T., see Mizushima, J. **197**, 193
Tack, J.W., see Hildebrand, G.E. **196**, 173
Takashima, Y., see Yuasa, H. **203**, 203
Takayama, K., see Ishikawa, T. **202**, 173
Takayama, K., see Junping, W. **203**, 61
Takayama, K., see Maitani, Y. **200**, 17
Takayama, K., see Morishita, M. **201**, 175
Takayama, K., see Obata, Y. **198**, 191
Takayama, K., see Onuki, Y. **198**, 147
Tamilvanan, S., B. Sa, Studies on in vitro release behaviour of indomethacin-loaded polystyrene microparticles **201**, 187
Tanaka, M., see Hanawa, T. **210**, 109
Tanaka, T., see Kaneo, Y. **201**, 59
Tan, M., J.E. Parkin, Route of decomposition of thiomersal (thimerosal) **208**, 23

Taylor, G., see Farr, S.J. **198**, 63
Taylor, G., see Seville, P.C. **195**, 13
Taylor, K.M.G., *Protein Formulation and Delivery*, by Eugene McNally (Ed.), Marcel Dekker, New York, 2000. ISBN 0-8247-7883-9 **206**, 107
Taylor, K.M.G., see Bridges, P.A. **204**, 69
Teesdale-Spittle, P., see Reason, M. **195**, 25
Tee, S.K., C. Marriott, X.M. Zeng, G.P. Martin, The use of different sugars as fine and coarse carriers for aerosolised salbutamol sulphate **208**, 111
Teijón, J.M., see Blanco, M.D. **202**, 29
Teixeira, F., see Veiga, F. **202**, 165
Tengamnuay, P., A. Sahamethapat, A. Sailasuta, A.K. Mitra, Chitosans as nasal absorption enhancers of peptides: comparison between free amine chitosans and soluble salts **197**, 53
Terada, K., see Yoshihashi, Y. **204**, 1
Tetley, L., see McPhail, D. **200**, 73
Thelly, T., see Bittner, B. **205**, 195
Thenmozhiyal, J.C., see Chan, L.W. **195**, 71
Theobald, F., see Loth, H. **209**, 95
Thomas, N.S., see Panchagnula, R. **201**, 131
Thomas, S., see Kwok, K.Y. **203**, 81
Thünemann, A.F., see Jenning, V. **199**, 167
Tijhof, I.M., see van Maanen, R.J. **196**, 85
Timmins, P., see Moore, V.A. **210**, 15
Timmins, P., see Moore, V.A. **210**, 29
Tissié, G., see Séchoy, O. **207**, 109
Titeva, S., see Michailova, V. **209**, 45
Tobyn, M.J., see Edge, S. **200**, 67
Todde, S., see Moresco, R.M. **204**, 101
Tokiwa, S., see Morishita, M. **201**, 175
Tokiwa, S., see Onuki, Y. **198**, 147
Toledo, D., see Dokka, S. **206**, 97
Tomaino, A., see Saija, A. **199**, 39
Tongwen, X., H. Binglin, A mechanism on the drug release into a perfect sink from a coated planar matrix with a super-saturation loading in the core **197**, 23
Torché, A.-M., H. Jouan, P. Le Corre, E. Albina, R. Primault, A. Jestin, R. Le Verge, Ex vivo and in situ PLGA microspheres uptake by pig ileal Peyer's patch segment **201**, 15
Torres, D., see Cuña, M. **199**, 151
Toth, I., see Shah, D.S. **208**, 41
Touw, D.J., see Abou El Hassan, M.A.I. **211**, 51
Towns-Andrews, E., see Eccleston, G.M. **203**, 127
Treiner, C., see Cherkaoui, I. **201**, 71
Tretyakov, L., see Wu, S.-L. **200**, 1
Trinquand, C., see Séchoy, O. **207**, 109
Trividic, A., see Raghavan, S.L. **193**, 231
Trojak, A., see Planinšek, O. **207**, 77
Trombetta, D., see Saija, A. **199**, 39
Trullas-Jimeno, A., see Bos, G.W. **211**, 79
Tsai, T.H., F.C. Cheng, L.C. Hung, C.F. Chen, Determination of unbound ceftriaxone in rat blood by on-line microdialysis and microbore liquid chromatography **193**, 21
Tsai, Y.-H., see Wu, P.-C. **209**, 87
Tsatouhas, G., see Prestidge, C.A. **198**, 201
Tsay, R.-J., see Chen, D. **203**, 141
Tucker, I.G., see Alany, R.G. **196**, 141
Tucker, I.G., see Bibby, D.C. **197**, 1
Tunçay, M., S. Çaliş, H.S. Kaş, M.T. Ercan, İ. Peksoy, A.A. Hincal, Diclofenac sodium incorporated PLGA (50:50) microspheres: formulation considerations and in vitro/in vivo evaluation **195**, 179
Tušar, L., see Gašperlin, M. **196**, 37
Tušar, M., see Gašperlin, M. **196**, 37
Twile, B., see Nielsen, H.W. **204**, 35

Ubrich, N., see Lamprecht, A. **196**, 177
Uccella, N., see Saija, A. **199**, 39
Uchegbu, I.F., see Arunothayanun, P. **201**, 7
Uchegbu, I.F., see McPhail, D. **200**, 73
Uchenna Agu, R., M. Jorissen, T. Willems, G. Van den Mooter, R. Kinget, N. Verbeke, P. Augustijns, Safety assessment of selected cyclodextrins — effect on ciliary activity using a human cell suspension culture model exhibiting in vitro ciliogenesis **193**, 219
Uemura, K., see Fukui, E. **204**, 7
Uemura, T., see Kaneo, Y. **201**, 59
Ueno, M., see Kogure, K. **210**, 117
Ueno, T., see Kaneo, Y. **201**, 59
Uesu, N.Y., E.A.G. Pineda, A.A.W. Hechenleitner, Microcrystalline cellulose from soybean husk: effects of solvent treatments on its properties as acetylsalicylic acid carrier **206**, 85
Ugwoke, M.I., R.U. Agu, M. Jorissen, P. Augustijns, R. Sciot, N. Verbeke, R. Kinget, Toxicological investigations of the effects carboxymethylcellulose on ciliary beat frequency of human nasal epithelial cells in primary suspension culture and in vivo on rabbit nasal mucosa **205**, 43
Unger, C., see Moog, R. **206**, 43
Utoguchi, N., K.L. Audus, Carrier-mediated transport of valproic acid in BeWo cells, a human trophoblast cell line **195**, 115
Uzun, C., see Şen, M. **203**, 149

Vachon, M.G., D. Chulia, **198**, 251
Vaithiyalingam, S.R., see Khan, M.A. **193**, 147
Vale, F.M., see Bettencourt, A. **197**, 161
Valenta, C., see Hadgraft, J. **200**, 243
Valenta, C., U. Siman, M. Kratzel, J. Hadgraft, The dermal delivery of lignocaine: influence of ion pairing **197**, 77
Van den Mooter, G., see Uchenna Agu, R. **193**, 219
Van den Mooter, G., see Van Gelder, J. **205**, 93
van der Vijgh, W.J.F., see Abou El Hassan, M.A.I. **211**, 51
van der Voort Maarschalk, K., see van Veen, B. **203**, 71
Van Gelder, J., M. Shafiee, E. De Clercq, F. Penninckx, G. Van den Mooter, R. Kinget, P. Augustijns, Species-dependent and site-specific intestinal metabolism of ester prodrugs **205**, 93
van Maanen, M.J., K. Doesburg Smits, J.M.A. Damen, A.J.R. Heck, J.H. Beijnen, Stability of thioTEPA and its metabolites, TEPA, monochloroTEPA and thioTEPA-mercapturate, in plasma and urine **200**, 187

van Maanen, R.J., I.M. Tijhof, J.M.A. Damen, J.W. Zwikker, J.H. Beijnen, The degradation of *N,N',N''*-triethylenephosphoramide in aqueous solutions: a qualitative and kinetic study **196**, 85
van Rensburg, F.J., see Beetge, E. **193**, 261
van Veen, B., K. van der Voort Maarschalk, G.K. Bolhuis, K. Zuurman, H.W. Frijlink, Tensile strength of tablets containing two materials with a different compaction behaviour **203**, 71
Vaution, C., see Cherkaoui, I. **201**, 71
Veiga, F., C. Fernandes, F. Teixeira, Oral bioavailability and hypoglycaemic activity of tolbutamide/cyclodextrin inclusion complexes **202**, 165
Venkatesan, N., S.P. Vyas, Polysaccharide coated liposomes for oral immunization — development and characterization **203**, 169
Verbeke, N., see Ikechukwu Ugwoke, M. **202**, 125
Verbeke, N., see Uchenna Agu, R. **193**, 219
Verbeke, N., see Ugwoke, M.I. **205**, 43
Vermehren, C., see Bjerregaard, S. **193**, 1
Veronese, F.M., see Caliceti, P. **211**, 57
Vervaet, C., see De |Brabander, C. **208**, 81
Vervaet, C., see De Brabander, C. **199**, 195
Vesalahti, J., see Krogars, K. **199**, 187
Vidal, M.M., see Ferreira, L. **194**, 169
Vidgren, M., see Karhu, M. **196**, 95
Vila Jato, J.L., see Cuña, M. **199**, 151
Villafuerte, L., see Espinoza, R. **201**, 165
V. Marshall, P., see D. Ticehurst, M. **193**, 247
Vodopivec, P., see Baumgartner, S. **195**, 125
Voinovich, D., M. Moneghini, B. Perissutti, J. Filipovic-Grcic, I. Grabnar, Preparation in high-shear mixer of sustained-release pellets by melt pelletisation **203**, 235
Volkova, N., see Ljunggren, L. **202**, 71
von Briesen, H., see Coester, C. **196**, 147
Vonk, P., see Schaafsma, S.H. **193**, 175
Vrečer, F., see Baumgartner, S. **195**, 125
Vyas, S.P., see Venkatesan, N. **203**, 169
Vyas, S.P., Y.K. Katare, V. Mishra, V. Sihorkar, Ligand directed macrophage targeting of amphotericin B loaded liposomes **210**, 1

Waicz, R., see Gessner, A. **196**, 245
Waisser, K., see Klimešová, V. **207**, 1
Wakabayashi, K., see Fujii, M. **205**, 117
Walter, I., see Mountfield, R.J. **211**, 89
Wang, J., W.-C. Shen, Gastric retention and stability of lipidized Bowman–Birk protease inhibitor in mice **204**, 111
Wang, W., Lyophilization and development of solid protein pharmaceuticals **203**, 1
Wang, Y.J., see Wu, S.-L. **200**, 1
Wardell, J.L., see Cox, P.J. **194**, 147
Warisnoicharoen, W., A.B. Lansley, M.J. Lawrence, Nonionic oil-in-water microemulsions: the effect of oil type on phase behaviour **198**, 7
Warren, S.J., see Farr, S.J. **198**, 63
Wartewig, S., see Duc Hanh, B. **204**, 145
Wartewig, S., see Duc Hanh, B. **204**, 151
Washington, C., see Waterhouse, E.T. **209**, 79
Washington, N., R.J.C. Steele, S.J. Jackson, D. Bush, J. Mason, D.A. Gill, K. Pitt, D.A. Rawlins, Determination of baseline human nasal pH and the effect of intranasally administered buffers **198**, 139
Washington, N., see Jackson, S.J. **205**, 173
Washington, N., see Waterhouse, E.T. **209**, 79
Watanabe, S., see Asai, Y. **193**, 189
Watanabe, Y., see Ishikawa, T. **202**, 173
Waterhouse, E.T., C. Washington, N. Washington, An investigation into the efficacy of the pectin based anti-reflux formulation-Aflurax **209**, 79
Weber, C., C. Coester, J. Kreuter, K. Langer, Desolvation process and surface characterisation of protein nanoparticles **194**, 91
Weber, C., J. Kreuter, K. Langer, Desolvation process and surface characteristics of HSA-nanoparticles **196**, 197
Weber, C., S. Reiss, K. Langer, Preparation of surface modified protein nanoparticles by introduction of sulfhydryl groups **211**, 67
Weerheim, A., see Ponec, M. **203**, 211
Welin-Berger, K., B. Bergenståhl, Inhibition of Ostwald ripening in local anesthetic emulsions by using hydrophobic excipients in the disperse phase **200**, 249
Welz, C., W. Neuhuber, H. Schreier, R. Repp, W. Rascher, A. Fahr, Nuclear gene targeting using negatively charged liposomes **196**, 251
Westrup, J., see Whitaker, M. **205**, 79
Whitaker, M., G.R. Baker, J. Westrup, P.A. Goulding, D.R. Rudd, R.M. Belchamber, M.P. Collins, Application of acoustic emission to the monitoring and end point determination of a high shear granulation process **205**, 79
Whitehead, L., J.H. Collett, J.T. Fell, Amoxycillin release from a floating dosage form based on alginates **210**, 45
Wigent, R.J., see DeCrosta, M.T. **198**, 113
Wigent, R.J., see Kosasih, A. **204**, 81
Wilderspin, A.F., see Shah, D.S. **208**, 41
Wilding, I.R., see Dobson, C.L. **195**, 63
Wilding, I.R., see Newman, S.P. **208**, 49
Wilhelm, A.J., see Abou El Hassan, M.A.I. **211**, 51
Willems, T., see Uchenna Agu, R. **193**, 219
Williams, A.C., see El Maghraby, G.M.M. **204**, 159
Williams, A.C., see El Maghraby, G.M.M. **196**, 63
Wilson, D.I., see Rough, S.L. **204**, 117
Winneroski, L.L., see Engel, G.L. **198**, 239
Wissing, S., D.Q.M. Craig, S.A. Barker, W.D. Moore, An investigation into the use of stepwise isothermal high sensitivity DSC as a means of detecting drug-excipient incompatibility **199**, 141
Wissing, S., see Liedtke, S. **196**, 183
Woodhouse, B., see Allender, C.J. **195**, 39
Woolfson, A.D., see McCarron, P.A. **193**, 37
Wulff, H., see Lukowski, G. **196**, 201
Wu, P.-C., Y.-B. Huang, J.J.-F. Chang, J.-S. Chang, Y.-H. Tsai, Evaluation of pharmacokinetics and pharmacodynamics of captopril from transdermal hydrophilic gels in nor-

motensive rabbits and spontaneously hypertensive rats **209**, 87
Wu, S.-L., D.M. Leung, L. Tretyakov, J. Hu, A. Guzzetta, Y.J. Wang, The formation and mechanism of multimerization in a freeze-dried peptide **200**, 1

Yahagi, R., Y. Machida, H. Onishi, Y. Machida, Mucoadhesive suppositories of ramosetron hydrochloride utilizing Carbopol® **193**, 205
Yajima, T., see Miwa, A. **195**, 81
Yalkowsky, S.H., see Alvarez-Núñez, F.A. **200**, 217
Yamaguchi, Y., see Kaneo, Y. **201**, 59
Yamamoto, K., see Kobayashi, Y. **193**, 137
Yang, Q., see Zhang, Q. **200**, 153
Yang, V.C., see Liang, J.F. **202**, 11
Yang, X., J.K.A. Ma, C.J. Malanga, Y. Rojanasakul, Characterization of proteolytic activities of pulmonary alveolar epithelium **195**, 93
Yazdanian, M., see Foster, K.A. **208**, 1
Ye, J., see Dokka, S. **206**, 97
Yeung, P.K.F., A. Jamieson, G.J. Smith, D. Fice, P.T. Pollak, Determination of plasma concentrations of losartan in patients by HPLC using solid phase extraction and UV detection **204**, 17
Yie, G., see Zhang, Q. **200**, 153
Yliruusi, J., see Korhonen, M. **197**, 143
Yliruusi, J., see Krogars, K. **199**, 187
Yliruusi, J., see Paavola, A. **199**, 85
Yli-Urpo, A., see Ahola, M. **195**, 219
Yli-Urpo, A., see Kortesuo, P. **200**, 223
Yonemochi, E., see Yoshihashi, Y. **204**, 1
York, P., *Particle–Particle Adhesion in Pharmaceutical Powder Handling*, Fridrun Podczeck, Imperial College Press, 1998. ISBN 1-86094-112-5 **206**, 105
York, P., see Crowley, K.J. **211**, 9
Yoshida, M., see Muramatsu, M. **199**, 77
Yoshihashi, Y., H. Kitano, E. Yonemochi, K. Terada, Quantitative correlation between initial dissolution rate and heat of fusion of drug substance **204**, 1
Yousefi-Rad, A., see Şenel, S. **193**, 197
Yuasa, H., J. Kaneshige, T. Ozeki, T. Kasai, T. Eguchi, N. Ishiwaki, Application of acid-treated yeast cell wall (AYC) as a pharmaceutical additive. II: effects of curing on the medicine release from AYC-coated tablets **209**, 69
Yuasa, H., M. Ooi, Y. Takashima, Y. Kanaya, Whisker growth of ℓ-menthol in coexistence with various excipients **203**, 203
Yuasa, H., see Kasai, T. **204**, 53
Yuasa, H., see Muramatsu, M. **199**, 77
Yuchun, X., L. Huizhou, C. Jiayong, Kinetics of base catalyzed racemization of ibuprofen enantiomers **196**, 21
Yuen, K.-H., see Billa, N. **201**, 109
Yuen, K.H., see Julianto, T. **200**, 53
Yuksel, N., A.E. Kanık, T. Baykara, Comparison of in vitro dissolution profiles by ANOVA-based, model-dependent and -independent methods **209**, 57

Zabel, M., see Flig, E. **196**, 11
Zapata, G., see Koumenis, I.L. **198**, 83
Zelkó, R., see Farkas, E. **193**, 239
Zeng, X.M., G.P. Martin, C. Marriott, J. Pritchard, The influence of carrier morphology on drug delivery by dry powder inhalers **200**, 93
Zeng, X.M., K.H. Pandhal, G.P. Martin, The influence of lactose carrier on the content homogeneity and dispersibility of beclomethasone dipropionate from dry powder aerosols **197**, 41
Zeng, X.M., see Tee, S.K. **208**, 111
Zhang, J.S., see Nur, A.O. **194**, 139
Zhang, L., see Chang, S.-L. **200**, 107
Zhang, Q., G. Yie, Y. Li, Q. Yang, T. Nagai, Studies on the cyclosporin A loaded stearic acid nanoparticles **200**, 153
Zhao, L., see Ng, K.-y. **193**, 157
Zhivkova, Z., I. Stankova, Stability of some novel thymidine, 5-bromo-2′-deoxyuridine and 3′-azido-2′-3′-dideoxythymidine analogues **200**, 181
Zhou, S.-l., see Jasti, B.R. **208**, 35
Zhu, K.J., see Jiang, H.L. **194**, 51
Zhu, K.J., see Shu, X.Z. **201**, 51
Zimmermann, E., R.H. Müller, K. Mäder, Influence of different parameters on reconstitution of lyophilized SLN **196**, 211
Zimmermann, E., see Schöler, N. **196**, 235
Zorc, B., see Lovrek, M. **200**, 59
Zorko, B., see Baumgartner, S. **195**, 125
Žukaitė, V., see Biziulevičius, G.A. **204**, 43
Zupan, J., see Gašperlin, M. **196**, 37
Zurowska-Pryczkowska, K., see Sznitowska, M. **202**, 161
Zuurman, K., see van Veen, B. **203**, 71
Zwikker, J.W., see van Maanen, R.J. **196**, 85

ELSEVIER

International Journal of Pharmaceutics 211 (2000) 119–135

international journal of pharmaceutics

www.elsevier.com/locate/ijpharm

Subject Index Volumes 193–211 (2000)

Absolute bioavailability (202), 89
Absorption (197), 213; (199), 17, 179
Absorption enhancement (205), 127
Absorption enhancers (193), 219
ACE inhibitors (210), 29
Acetaminophen (203), 159
Acetazolamide (199), 119
Acetone precipitated enzyme preparation solutions (204), 43
Acetylsalicylic acid (198), 39; (206), 85
Acid-treated yeast cell wall (AYC) (209), 69
Acid type (194), 229
Acoustic emission (205), 79
Acrylic microspheres (196), 75
Acrylic polymer (204), 171
Acrylic resin (196), 75
Activation energy of hydrolytic release (204), 81
Acute renal failures (194), 221
Adhesion (199), 29; (200), 121
Adjuvant (196), 135
β_2-Adrenergic receptors (204), 101
Adsorption (201), 71
Aerodynamic particle size (197), 41
Aerosol (199), 7; (204), 69; (210), 83
Aerosol deposition (198), 63
Aerosol inhaler (206), 75
Aerosolisation (197), 221
Aerosols (200), 87
Agglomerated particles (208), 101
Agglomeration (193), 175, 247
Aggregation (203), 1
Aggregation prevention (203), 81
Aging (197), 117; (208), 13
Air flow (206), 75
Albumin–liposome interaction (195), 207
Albumin microspheres (195), 147
Alcohols (196), 141
Alginate-chitosan (206), 23
Alginate-poly-*l*-lysine microparticles (210), 51
Alginic acid (207), 109
Alkylcarbonyl prodrugs (205), 53
Alkyloxycarbonyl prodrugs (205), 53
Amberlite® IRP-69 (205), 173
Amino acids (200), 181
Amino group determination (194), 91; (196), 197
Aminoguanidine (194), 209
Aminopeptidase (200), 261
Amorphous state (204), 1; (207), 49
Amorphous drug (205), 65
Amorphous methyl-β-cyclodextrin (193), 85
Amorphous polymer (196), 27
Amorphous powders (206), 75
Amorphous quantification (207), 57
Amoxycillin (201), 1; (210), 45
Amphotericin B (193), 97; (210), 1
Ampicillin (201), 1
Amylodextrin (204), 23
Amylolytic enzymes (204), 43
Androgenetic alopecia (194), 125
Anesthetic potencies (202), 41
Anhydrate (198), 239
Annealing (197), 117
ANOVA-based methods (209), 57
Antacid (209), 79
Anti-allergic (197), 213
Anti-amoebic agents (194), 15
Antibodies (206), 23
Antibody conjugation (205), 101
Antibody isolation (195), 147
Antibody linkage (195), 147

PII: S0378-5173(00)00647-5

Antibody production (195), 147
Anticancer action (203), 61
Anticonvulsant (202), 79
Antiemetic (193), 205
Antifungal (193), 197
Anti-interleukin-8 antibody (198), 83
Anti-lisinopril IgG (206), 23
Antimycobacterial activity (207), 1
Antioxidant (198), 1; (199), 39
Antiprotozoal (196), 253
Anti-reflux agent (209), 79
Antisense oligonucleotides (208), 35
Antiviral (205), 93
Aphidicolin (196), 253
Apolipoprotein A-I_M (194), 21
Apomorphine (202), 125; (205), 43
Arabinogalactan (201), 59
Archaeal lipid liposomes (194), 39
Archaeosomes (194), 39
Artificial intelligence (196), 27
Aseptic production (196), 151
Asialoglycoprotein receptor (201), 59
Aspergillus flavus (203), 109
Aspirin (199), 141
Atenolol (194), 249
Atomic absorption spectrometry (205), 35
Atomic force microscopy (200), 271
ATP release (193), 123
Atrial natriuretic peptide (200), 1
Attenuated total reflectance (204), 145, 151
Avidin (196), 147
Azone (203), 245
Azone® (197), 69; (202), 133
Azopolymers (198), 71
Aztreonam determination (205), 35

Bacillus subtilis culture filtrates (204), 43
Back diffusion (193), 27
Bacterial degradation (198), 71
Barrier function (211), 29
Barrier function. (195), 189
Base catalysis (196), 21
Batches (204), 61
B cell lymphoma (205), 101
BDP (197), 41
Beads (199), 129; (206), 23
Beclomethasone dipropionate (197), 41
Benefit-risk ratio (196), 165
Benzathine penicillin G (208), 71
Benzoic acid (194), 117
4-(benzylsulfanyl)pyridine-2-carbonitrile (207), 1
4-(benzylsulfanyl)pyridine-2-carbothioamide (207), 1
Beta-cyclodextrin (195), 71
Biexponential decay model (193), 21
Bifidobacteria (210), 51
Bilayer lipid membranes (205), 135
Binary and multi-component mixtures (206), 63
Binary mixture (201), 1; (203), 71
Binding study (211), 29
Bioactivity (198), 83
Bioadhesion (195), 147; (200), 271
Bioavailability (193), 137; (198), 239; (199), 159; (202), 165; (204), 35; (205), 159; (207), 109; (208), 81; (209), 37
Biocompatibility (194), 261
Biodisposition (201), 59
Biodistribution (203), 61
Bioerodible polymers (196), 173
Bioflavonoid (205), 135
Biomaterial (197), 161
Biomimetic (195), 39
Biopharmaceutics (201), 131
Biopharmaceutics Classification System (200), 41
Biosensor (195), 25
Bisacodyl (196), 11
Blood–brain barrier (193), 157; (201), 239; (202), 79
Blood glucose monitoring (193), 27
Blood pressure (209), 87
Boiling point (202), 41
Bone cement (197), 161
Bone filler (206), 1
Bovine serum albumin (195), 147
Bowman–Birk protease inhibitor (204), 111
Brain targeting (195), 197
Brittle fracture (197), 95
Brucellosis (196), 115
BSA (196), 177
Buccal (195), 29; (208), 35
Buccal administration (209), 37
Buccal delivery system (204), 137
Buccal enzyme activity (200), 261
Buccal mucosa permeation (195), 171
Buccal permeability (194), 155
Buccal permeation (195), 35

Buffer (198), 139
Buffer concentration (197), 87
Bumetanide (194), 193; (204), 35
Buprenorphine (205), 159

Caco-2 cells (200), 41; (207), 21; (210), 15, 29; (211), 29
Caecal amoebiasis of rats (194), 15
Caffeic acid (199), 39
Caffeine (207), 7
Calcitonin (200), 107
Calorimeter (201), 1
Calorimetry (198), 113; (199), 95; (202), 71
Calu-3 (208), 1
Cancer (200), 27
Capacity (202), 141
Capillary condensation (203), 203
Capillary penetration techniques (198), 201
Capsaicin (195), 55
Captopril (193), 147; (194), 139; (209), 87
Carbamazepine (193), 137
Carbomer (199), 129
Carbopol® (193), 205; (199) 77, 129
Carboxyfluorescein release (207), 39
Carboxymethylated MS (195), 147
Carboxymethylated mucus (195), 147
Carboxymethylcellulose (194), 239; (202), 125; (205), 43
Carboxymethylcellulose-sodium (209), 45
Carboxypeptidase (200), 261
Carrageenan (200), 207
Carrier systems (196), 95
Carteolol (207), 109
Cascade impaction (210), 83
Casein (198), 157
Cast film (209), 69
Cationic lipid (197), 221
Cationic liposomes (197), 233
Cationic polymeric carriers (211), 79
CD (194), 69
Cefadroxil (201), 29
Cefazolin (198), 167
Ceftriaxone (193), 21
Cefuroxime axetil (195), 137; (201), 211; (202), 89
Cell culture (193), 219; (194), 209
Cellular activation (195), 17
Cellular uptake (210), 61
Central composite designs (203), 159
Cerebrospinal fluid (CSF) (195), 197
Cetrimide/cetostearyl alcohol ternary system (203), 127
Cetyl alcohol (197), 35
Cetyl palmitate (196), 201
CFC-113 (200), 279
Characterization (196), 27
Chemical instability (196), 85
Chemical stability (197), 153
Chiral HPLC (199), 159
Chiral inversion (199), 159
Chitosan (193), 197; (194), 1; (196), 51; (200), 73; (201), 51; (203), 89
Chitosan citrate (198), 97
Chitosan derivatives (194), 1
Chitosan–gelatin-sponge (194), 229
Chitosan microspheres (202), 29
Chitosan salts (197), 53
Chlorhexidine gluconate (193), 197
Chlorofluorocarbons (201), 89
7-Chlorokynurenic acid (202), 79
Cholesterol (205), 183
Cholestyramine (205), 173
Chow's test of structural change (209), 95
(±)-[^{11}C]ICI 118551 (204), 101
Ciliary beat frequency (193), 219; (205), 43
Cilio-toxicity (193), 219
Ciprofloxacin (204), 97
Circadian rhythm (198), 139
Circular dichroism (193), 97; (194), 21; (201), 37
Citric acid (201), 165
Clinical response (208), 49
Clonazepam (199), 65; (205), 109
Clonazepam release (200), 231
Coated pellets (197), 169
Coated planar matrix (197), 23
Coated tablet (198), 97
Coating material (199), 77; (204), 53
Cohesiveness (194), 239
Collagen and gelatin microspheres (193), 113
Colloidal drug carrier (196), 211
Colonic drug delivery (197), 169, 181
Colon targeting (204), 7
Colon targeting (199), 187
Colorimetry (205), 35
Compaction (198), 113
Compaction calorimeter (198), 113
Compaction heat (198), 113

Compaction work (198), 113
Comparative bioavailability (200), 53
Comparison of dissolution profiles (209), 57
Compatibility (198), 97; (199), 141
Complement (205), 183
Complex coacervation (196), 223
Composite rotative design (197), 153
Compound 73/602 (197), 213
Compressibility (198), 51
Compression (193), 63
Compression behavior (197), 95
Compression force (208), 101
Compression speed (208), 101
Confocal laser scanning microscopy (CLSM) (196), 223
Confocal microscopy (207), 89
Conformation (194), 69
Conformational analysis (199), 59
Conjugate fragments (204), 81
Contact angle (198), 201; (207), 77
Contamination (195), 7
Continuous flow rheometry (196), 227
Controlled release (193), 113; (194), 139, 169, 229; (195), 219, 229; (196), 1; (197), 23; (199), 77, 85; (200), 115, 133; (201), 29, 109, 151; (202), 125; (205), 195; (207), 7, 99
Controlled release matrix tablets (200), 207
Controlled-release suspensions (199), 151
Core release (205), 147
Core-shell structure (211), 1
Cornea (207), 89
Cosmetics (196), 51
Cosolvent (193), 231; (204), 35
Cosurfactants (196), 141
Covalent linkage (196), 147
Crack formation (204), 23
Critical micelle concentration (210), 109
Critical stress intensity factor (209), 27
Cromolyn (198), 167
Cross-linking (199), 77
Crushing strength (208), 101
Cryoprotection (203), 1
Crystal habit (200), 93; (208), 87
Crystalline form (201), 187; (207), 49, 57
Crystallinity (193), 247; (204), 1
Crystallisation (196), 201; (201), 79; (208), 87
Crystals (194), 147; (195), 45; (199), 167; (204), 133
Crystal structure (208), 87
Cubic phase of glyceryl monooleate (204), 137
Curing (209), 69
Cyclodextrin (197), 1; (200), 127; (211), 19
β-Cyclodextrin (193), 85
Cyclodextrins (193), 219; (202), 165
Cyclohexanol derivatives (198), 191
Cyclosporin A (194), 201; (200), 153
Cyclosporine (194), 221
Cylinder-plate method (203), 109
Cytarabine (202), 29
Cytochrome P450 (211), 89
Cytokines (196), 235
Cytotoxicity (196), 235; (210), 61

DEAE-dextran (206), 97
Deamidation (203), 115
Decompression (198), 113
Degradation (208), 23
Degradation kinetics (196), 85
Degradation pathways (203), 115
Denaturation (203), 1
Dendrimers (197), 239; (208), 41
Densification (203), 71
Deoxyuridine (193), 113
Deposition (200), 93, 279
Dermal absorption (196), 165
Dermal bioavailability (204), 151
Dermal delivery (200), 243
Desmuramyldipeptide (199), 59
Desolvation procedure (194), 91; (196), 197
Destructive force (208), 61
Dexmedetomidine HCl (200), 223
Dextran-methylprednisolone conjugate (207), 71
Dextrose (202), 47
Diabetes (193), 27
Dialysis equilibria (200), 207
Dialysis method (207), 99
Diazepam (199), 65
Diclofenac sodium (195), 179; (201), 109
Diethylene glycol monoethyl ether (195), 171
Diethylhexyl phthalate (210), 109
Difference factor (209), 57
Differential scanning calorimetry (DSC) (193), 85; (194), 21; (195), 207; (199), 141; (200), 161; (201), 7, 211; (204), 1; (205), 15; (208), 87
Diffusion (197), 203; (198), 229; (200), 115
Diffusion cell experiments (205), 53

Diffusion chamber (195), 55
Diffusion constant (205), 117
Diltiazem (195), 159; (204), 127
Diltiazem HCl (200), 207
2,2′-Dimethylacryloyloxyazobenzene (198), 71
Dimethyl-β-cyclodextrin (197), 53
Diols (196), 141
Dipeptides (210), 29
Dipeptide transporter system (DTS) (210), 29
Direct compression (193), 167; (197), 107
Disodium cromoglycate (200), 87; (206), 75
Dispersion (200), 93
Dissolution (196), 187; (201), 199, 221
Dissolution coefficient (204), 151
Dissolution profile (203), 141
Dissolution properties (193), 85
Dissolution rate (193), 137; (195), 45; (204), 1
di/tri/oligopeptide transport system (210), 15
DNA (211), 79
DNA carrier (196), 257
DNA condensation (210), 97
Docosahexaenoic acid (198), 147; (201), 175
Doehlert design (203), 235
Dogs (194), 181
Double emulsion technique (196), 177
Doxorubicin (203), 61
Doxorubicin-loaded solid lipid nanospheres (210), 61
5-Doxyl stearic acid (197), 193
Draize eye test (207), 89
Drug accumulation in stratum corneum and dermis (209), 95
Drug carrier (200), 153
Drug controlled release (201), 51
Drug delivery (205), 165; (207), 65; (211), 57
Drug delivery system (DDS) (194), 1; (205), 183
Drug encapsulation (196), 219
Drug-fatty acid salt (211), 9
Drug incorporation (199), 95
Drug loading (193), 167
Drug–polymer complex (200), 207
Drug release (199), 167; (200), 223; (201), 187; (203), 179; (210), 45
Drug release from suspension (204), 145, 151
Drug release mechanism (202), 21; (204), 23
Drug solubility (193), 167
Drug targeting (196), 165, 231, 245, 253; (202), 1
Drug transport (201), 239
Drying (193), 13
Dry powder aerosols (197), 41
Dry powder inhalers (197), 41; (200), 93; (208), 111
Dural permeation (199), 85
Dynamic analysis (199), 7
Dynamic laser speckle (199), 205
Dynamic vapour sorption (193), 247; (207), 49

Econazole (193), 85
Effective diffusion coefficient (204), 145
Eicosapentaenoic acid (201), 175
Ejection (198), 113
Elastic energy/plastic energy ratio (208), 101
Elastic recovery (208), 101
Electron paramagnetic resonance (196), 241; (200), 161
Electron paramagnetic resonance spectroscopy (197), 193
Electroporation (202), 121
Electrostatic charge (195), 7
ELISA (195), 147
Emission tomography (204), 101
Emulsifying wax (203), 127
Emulsion (196), 37; (198), 147; (201), 175; (211), 29
Enantiomers (199), 159; (202), 97
Encapsulation (196), 177
Endophthalmitis (204), 97
Enhanced membrane transport (206), 35
Enhancer (195), 17; (197), 13; (200), 17; (201), 121; (202), 133; (209), 37; (210), 69
Entamoeba histolytica (194), 15
Enteric coated (204), 7
Enthalpy (202), 71
Enthalpy of solution (201), 1
Entropy (198), 1
Enzymatic degradation (197), 181
Enzyme activity (195), 93
Enzyme drugs (202), 11
Enzyme inhibitors (197), 87
Epidermal lipids (203), 211
Epidermis (197), 233
Epidural administration (203), 227
Epithelial cells (195), 93
Equilibrium solubility (195), 239
Equilibrium swelling (207), 65
Erosion (203), 179
Erythema (200), 195

Erythrocyte (210), 117
Erythromycin–tretinoin topical solution (197), 153
Ester (195), 13
Esterase (200), 261; (205), 93
Ethyl formate (195), 103
Eudragit (195), 45; (201), 79; (202), 103; (203), 141
Eudragit® RS and RL (199), 151
Eudragit™ S 100 (199), 187
Eudragits® (197), 181
Eutectic (197), 35
Excess molar enthalpy (201), 1
Excipient (195), 81; (199), 141; (203), 1, 203
Exopolymer (207), 39
Experimental arthritis (195), 179
Experimental design (193), 147; (198), 213; (205), 3; (206), 55
Extended Hansen method (194), 117
Extruded films (202), 63
Extrusion-spheronization (199), 129
Ex vivo experiment (201), 15
Ex vivo model (197), 233

FACS (195), 17
Factorial design (193), 1
Factorial design Atovaquone (206), 55
Factor VIII (194), 69
Fat (196), 187
Fatty acid (195), 25
Fatty-acid ester (205), 117
FB-ratio (194), 261
Fenoprofen (198), 167
Ferguson principle (202), 41
Fermosorb-type preparations (204), 43
Ferulic acid (199), 39
Film-coating (197), 181
Film former (198), 97
Film structure (209), 69
Finasteride (194), 125
FITC (201), 59
FITC-dextran (193), 113
Flame emission spectroscopy (195), 137
Flexibility (194), 201
Floating (195), 125
Floating beads (198), 157
Floating dosage forms (210), 45
Flow injection UV spectrophotometry (202), 113
Flow through dissolution (201), 199; (206), 55
Flufenamic acid (209), 95
Fluid bed (193), 175
Fluid bed granulation (207), 77
Fluorescence (193), 97; (200), 279; (201), 37
Fluorescence microscopy (201), 59
Fluorescent dye (211), 29
Flutamide (194), 125
Fluticasone propionate (200), 279
Flux (198), 179
Formulation (193), 147; (203), 1; (211), 89
Formulation effects (207), 7
Formulation parameters (194), 181
Fourier transform infrared spectroscopy (204), 145, 151
FPIA (197), 129
Fractional factorial design (205), 3
Fracture toughness (209), 27
Free amine chitosans (197), 53
Free energy (198), 1
Free flowing (210), 51
Free radical (205), 23
Freeze-drying (203), 1, 81
Furosemide solid dispersions (195), 45

Galactosylated poly-L-lysine (202), 151
Gamma scintigraphy (196), 95; (198), 63; (201), 109; (205), 173
Gas producing cell (193), 57
Gastric acid resistance (210), 51
Gastric residence (195), 125; (205), 173
Gastric retention (204), 111; (210), 45
Gastrointestinal absorption (204), 111
Gastrointestinal therapeutic system (193), 147
Gastrointestinal transit (195), 63; (201), 109; (208), 61
Gastro-oesophageal reflux (209), 79
GC (196), 85
GC-headspace analysis (195), 159
Gelatin (194), 91; (196), 147; (198), 157
Gelatin hollow type rectal suppository (194), 81
Gelatin methotrexate conjugates (204), 81
Gelation (211), 37
Geliderm-tensid 3000 (KLHT) (206), 13
Gelucire® (208), 13
Gemcitabine (206), 43
Gemfibrozil (200), 59

Gene delivery (196), 257; (208), 41; (210), 97
Gene expression (208), 41
Gene therapy (197), 221, 233; (210), 97
Gene transfection (206), 97
Gentamicin (209), 15
Gentamicin sulphate (196), 115
Geometry (201), 151
GI tract (194), 39
Glass transition temperature (202), 63, (203), 1
Glaucomatous pigmented rabbits (198), 29
Glibenclamide (195), 239
Glucagon (203), 115
Glucose (202), 47
Glucosylamines (202), 47
Glutaminyl (203), 115
Glutaraldehyde crosslinking (194), 229
Glyceride (196), 219
Glyceryl monooleate (195), 29, 35
Glycol chitosan (200), 73
Glycolic acid (196), 51
Glycotargeting (201), 59
Granulate properties (207), 77
Granulation (198), 51
Guanidine (194), 209

Halofantrine (205), 65
Heart rate (209), 87
Heavy metal contamination (196), 169
Heckel plot (193), 63
Hemolysis (194), 261
Heparin (202), 11
Hepatoma cells (202), 151
Hepatotropic carrier (201), 59
Hexagonal and lamellar structure (193), 239
High performance size exclusion chromatography (201), 59
High pressure homogenisation (196), 169, 183
High shear (198), 51
High shear granulation (205), 79
High shear mixer (203), 235
Histological change (209), 37
Histological studies (202), 29
Hot melt (202), 63
Hot-stage-microscopy (193), 85
HPLC (196), 11, 215; (200), 279; (204), 17; (211), 51
HPMC, Sustained release (201), 165
5-HT-1a receptor antagonist (195), 197
Human (194), 155; (198), 139; (200), 261
Human epidermis (197), 77
Human growth hormone (197), 13
Human serum albumin (194), 91; (195), 207; (196), 197; (211), 67
Human skin (193), 27; (194), 249
Human stratum corneum (197), 193, 203
Hydrate (198), 167; (201), 221
Hydration (200), 161; (203), 179
Hydrochloride salt (198), 239
Hydrocortisone (198), 179; (209), 95
Hydrocortisone acetate (193), 231
Hydrocortisone skin content (198), 179
Hydrodynamics (201), 199
Hydrofluoroalkanes (201), 89
Hydrogel (194), 169; (203), 89, 149; (205), 109
Hydrogel nanoparticles (202), 1
Hydrogen bond (203), 203
Hydrogen bonding (201), 239; (204), 133
Hydrolysis (203), 115; (206), 43
Hydrolytic release from protein conjugates (204), 81
Hydrophile–lipophile balance (197), 143
Hydrophilic matrix (195), 229; (201), 151
Hydrophobic barrier (205), 135
Hydrophobic drugs, Dissolution (195), 1
Hydrophobic ion pairing (203), 193
Hydroxpropyl-β-cyclodextrin (198), 229
Hydroxyethyl methacrylate (194), 169
Hydroxypropylcellulose (202), 63; (204), 7
Hydroxypropylcellulose methylmethacrylate (202), 21
Hydroxypropyl-β-cyclodextrin (197), 53
Hydroxypropyl methylcellulose (193), 231; (195), 229; (198), 179, 229; (200), 161; (201), 151; (202), 173; (203), 99; (204), 171; (209), 45.
Hydroxypropyl methylcellulose acetate succinate (199), 187
Hypoglycaemic activity (202), 165

Ibuprofen (193), 261; (194), 117; (196), 1; (197), 35, 239; (198), 229; (199), 159, 195, 205; (200), 243; (201), 79; (208), 81; (209), 109
Ibuprofen enantiomer (196), 21
Ibuprofen lysinate (199), 159
Ibuprofen·Na (199), 85
Ileal brake (195), 63
Image analysis (202), 21; (207), 89

Immobilization (206), 23
Immobilization conditions (204), 43
Immune-stimulating complex (196), 135
Immunoliposome (193), 157; (205), 101
Immunosuppression (207), 71
Inclusion complexes (200), 127; (202), 165
Indomethacin (193), 123, 261; (194), 81; (201), 187; (205), 117
Influence of pH and concentration antioxidant (197), 153
Influence of skin lipid composition and vehicles (209), 95
Infrared sensor (195), 81
Infra-red spectroscopy (201), 221
Infrared spectroscopy (195), 45
Inhalation mapping (199), 7
Inhalation powders (196), 95
Inhaled drugs (208), 49
Inhaler (193), 227; (195), 13
Inhibition (211), 89
Injectable (199), 85
In situ experiment (201), 15
In situ implant (194), 181
Insoluble polymers (197), 169
Insulin (198), 147; (201), 175; (205), 127; (211), 57
Interaction (195), 71
Interfacial adsorption (203), 99
Interfacial cross-linking (211), 19
Intermembrane protein transfer (210), 117
Internal energy change (198), 113
Internal standard (196), 231
Interparticle bonding (203), 71
Interpolymer complex (202), 103
Interpolymeric hydrogel (207), 65
Intestinal absorption (201), 175
Intestinal first-pass effect (194), 193
Intestinal instability (199), 17
Intestinal metabolism (205), 93
Intestinal permeability (199), 17
Intestinal tissue (197), 13.
Intracellular calcium (200), 17
Intracelullar infections (196), 115
Intranasal administration (199), 65
Intraocular pressure (198), 29; (199), 119; (207), 109
Intrathecal administration (203), 227
Intrathecal bioavailability (203), 227
Inverse phase gas chromatography (193), 13
In vitro diffusion (193), 231
In vitro dissolution (211), 9
In vitro release (195), 29; (197), 23; (205), 109
In vitro release kinetic (208), 71
In vitro skin permeation (200), 127
Ion exchange resin (199); 151; (205), 173
Ionic complex (197), 181
Ionisation (210), 69
Ion-pair complex (205), 35
Ion pairing (197), 77
Iontophoresis (197), 69; (200), 107, 195; (201), 121; (202), 121
γ-Irradiation (198), 213
Irritation (200), 195
ISCOM (196), 135
Isosorbide dinitrate (199), 1
Isosorbide mononitrate (199), 1
Isothermal microcalorimetry (193), 13
Isothermal transient ionic current (199), 179
i.v. formulation (211), 51

Karaya gum (193), 73; (203), 179
Ketoconazole (198), 1
Ketoprofen (193), 261; (198), 191; (205), 117; (206), 13
Ketorolac (209), 1
Kinetics (202), 47

Lactose (195), 7; (196), 95; (197), 41; (198), 51; (200), 93; (207), 49; (208), 111
Lag time (198), 179; (204), 53; (209), 69
Lamellar phase (203), 127
Laser Doppler velocimetry (200), 195
Laxative effect (196), 11
LC–MS (200), 1
Lead compound (198), 191
Lecithin (193), 49; (196), 131
Lecithin vesicles (194), 201
Leishmania (196), 253
Leu-enkephalin (200), 261
Leuprolide acetate (203), 193
Leurpolide acetate (194), 181
LHRH (195), 93
Lidocaine (194), 103; (211), 37
Lidocaine–bupivacaine (203), 227
Lidocaine hydrochloride (201), 121
Lidocaine–menthol binary systems (206), 35
Ligand binding (195), 147

Light scattering (198), 29
Lignocaine (197), 77; (200), 243
Linoleic acid (207), 21
Lipid emulsion (205), 127
Lipids (196), 215
Lipid solubility (205), 53
Lipid vesicles (204), 159
Lipophilicity (194), 155; (201), 131
Lipophilic spin probes (196), 241
Liposoluble derivatives (194), 61
Liposomal doxorubicin (205), 101
Liposome characterization (198), 29
Liposomes (193), 97, 157; (195), 207; (196), 51, 151, 251; (198), 213; (199), 85; (200), 73; (201), 37; (203), 99, 169, 255; (204), 69, 159; (205), 183; (206), 43, 97; (210), 1
Liposomes-ultradeformable (196), 63
Liquid aerosol generator (198), 63
Liquid crystalline phase (195), 29, 35
Liquid crystals (193), 239
Liquid lipids (205), 15
Liquid phase migration (204), 117
ℓ-Menthol (198), 191; (203), 203
Loading capacity (199), 167; (205), 15
Local anesthetics (200), 249
Location (196), 241
Log *P* (198), 179
Long circulating nanoparticles (202), 1
Long circulation (203), 61
Long-term stability (196), 161
Losartan (204), 17
Loss tangent (197), 143
Low melting point binder (211), 9
Low-substituted hydroxypropylcellulose (L-HPC) (197), 107
Lung (195), 13, 93; (197), 221
Lung deposition (193), 227; (208), 49
LY333531 (198), 239
Lymphocyte proliferation (207), 71
Lyophilisation (198), 213
Lyophilization (196), 211; (200), 1
Lyoprotectant (203), 81
Lyoprotection (203), 1
Lysophospholipid (206), 43
Lysozyme (205), 23
Lytic enzymes (204), 43

Macrogol 6000 (202), 173; (206), 13
Macromolecular prodrug (200), 59
Macromolecule (203), 89
Macrophages (206), 97
Macrophage targeting (210), 1
Magnesium stearate (199), 141
Malarone (206), 55
Mannitol (200), 1; (208), 111
Mathematical analysis (197), 23
Matrices (203), 179
Matrix (195), 125; (196), 105; (208), 81
Matrix tablet (202), 21
Mechanical property (200), 67
Mechanism of drug release (197), 169
Melt extrusion (199), 195
Melt granulation (211), 9
Melting properties (206), 35
Melt pelletisation (203), 235
Membrane (193), 189
Membrane diffusion (207), 7
Membrane fusion (210), 117
Mesylate salt (198), 239
Metabolism (196), 11; (197), 129; (204), 17
Metal erosion (196), 169
Metal ions (194), 69
Metered dose inhaler (198), 63 (200), 87; (201), 89
Methanol/water (200), 279
Methodology (193), 63
Methyl cellulose (193), 231
Methylmethacrylate (197), 161
Methylprednisolone (207), 71
Metoclopramide-HCl (196), 193
Metoprolol (194), 249; (202), 97
Mice (194), 125
Micellar systems (207), 21
Micelle (199), 95; (210), 109
Micellization (211), 37
Microbiological assay (203), 109
Microcalorimetry (193), 247; (195), 17; (197), 117
Microcapsules (196), 223; (199), 151; (211), 19
Microcrystalline cellulose (204), 117; (206), 85; (209), 27
Microdialysis (193), 21; (203), 227
Microemulsion (194), 103; (196), 131, 141; (205), 65; (199), 17; (205), 65; (211), 37
Microencapsulation (193), 113; (195), 103; (196), 1, 173, 223; (205), 23, 147
Micromeritic properties (201), 79

Micronisation (193), 247
Microparticle characterization (203), 159
Microparticles (200), 133
Microprocessor-controlled device (198), 63
Microsomes (211), 89
Microsphere (195), 103, 137; (196), 115; (197), 1; (201), 211; (202), 125; (203), 193; (211), 57
Mini-matrix tablets (193), 73
Mini-tablet (199), 195; (208), 81
Miotic effect (202), 161
Misoprostol (203), 141
Mixed hydrophilic matrices (209), 45
Mixing homogeneity (197), 41
Mixture design (196), 131
Model-dependent methods (209), 57
Model-independent methods (209), 57
Modeling (196), 37; (200), 115; (201), 151; (207), 31
Modified release (197), 1
Moisture (195), 7; (204), 23
Moisture content (209), 27
Molar conductivity (201), 121
Molecular conjugate (202), 151
Molecular interaction (205), 135
Molecularly imprinted polymer (195), 39
Molecular modelling (197), 203
Molecular recognition (195), 39
Monkey (194), 155; (204), 101
Monocarbamate derivative (199), 65
Monocarboxylic acid transporter (195), 115
MonochloroTEPA (200), 187
Monoclonal antibody (205), 101
Monohydrate (198), 239
Monohydroxyethylrutoside (211), 51
Monolayer (203), 245
Monte Carlo approach (199), 59
Morphine sulfate powders (198), 201
Morphology (203), 211
Moving front kinetics (202), 21
^{99m}Tc-labelling (196), 95
Mucoadhesion (194), 239; (200), 271; (205), 43
Mucoadhesive (209), 37
Mucoadhesive strength (195), 147
Mucoadhesive suppository (193), 205
Mucosal delivery (208), 35
Mucosal inflammation (205), 43
Mucus (195), 147
Multi-component systems (200), 73
Multimerization (200), 1
Multiple administration (198), 147
Multiple dose (202), 97
Multiple layer vesicles (MLV) (196), 151
Multiple linear regression (209), 95
Multiple unit dosage form (199), 195
Multivariate regression analysis (197), 203

N-3-alkyl oxyhydroxypropyl-L-arginine (197), 193
Nanocapsules (208), 71
Nanoemulsions (196), 183; (208), 71
Nanoparticles (193), 37; (194), 91; (196), 147, 155, 177, 183, 197, 231, 245, 257; (199), 95; (200), 153; (205), 109; (211), 67
Nanosuspension (196), 161, 169, 253
Naproxen (193), 261; (200), 161
Nasal (198), 139; (204), 35; (205), 159
Nasal absorption (205), 127
Nasal absorption enhancers (197), 53
Nasal administration (195), 197; (200), 17
Nasal drug delivery (202), 125; (205), 43
Near infra-red (207), 49
Near-infrared reflectance spectroscopy (206), 63
Nebulisation (197), 221
Nebuliser (204), 69
Nedocromil sodium (200), 87
Neural networks (196), 37
New antarctica bacterial species *Pseudoalteromonas antarctica* NF_3 (207), 39
New crystal form (195), 239
New drug development (201), 131
Nifedipine (202), 173
Niosomes (193), 123; (200), 73; (201), 7
N-isopropylacrylamide (209), 1
Nitroglycerin (193), 57
NMDA-receptor (202), 79
N-methyl-2-pyrrolidone (205), 195
NMR (205), 15
N, *N*-dimethylacetamide (205), 195
N,*N*-Dimethyl-alkylamine-*N*-oxide surfactants (198), 7
Non-disintegrating tablet (204), 47
Non-Fickian diffusion (195), 125
Nonionic emulsifiers (195), 189
Nonionic oil-in-water microemulsions (198), 7
Non-ionic surfactant (202), 133; (209), 109
Non-linear fitting (198), 39
Non-steroidal anti inflammatory (207), 31

Non-viral vectors (208), 41
Norfloxacin (207), 99
Normal skin (195), 189
Nose (198), 139
Nozzle (193), 175
NSAID (209), 1
Nuclear gene targeting (196), 251
Nuclear magnetic resonance (200), 161; (201), 221
Nucleoside analogue (206), 43
Nucleosides (194), 15
Nystatin (201), 37

Octanol–water (200), 217
Octyl glucoside (207), 39
Ocular delivery (209), 1
Ocular penetration (204), 91
Oestradiol (196), 63; (204), 159
Ofloxacin (204), 91
Oleic acid (195), 63; (204), 137; (211), 9
Olfactory pathway (195), 197
O-palmitoyl mannan (OPM) (210), 1
O-palmitoylpullulan (203), 169
O-Phtaldialdehyde (209), 15
Ophthalmic delivery (207), 109
Optimization (203), 159
Oral absorption (200), 41; (205), 93
Oral cavity (200), 271
Oral delivery (197), 13; (204), 7
Oral delivery system (194), 39; (198), 157; (202), 103
Oral immunization (203), 169
Oral mucosal delivery (193), 197
Organic cation (194), 209
OROS® systems (204), 47
Oscillatory testing (196), 227
Osmotic behaviour (193), 1
Osmotic pump (205), 195
Ostwald ripening (200), 249
7-Oxoacyl-L-alanyl-D-isoglutamines (199), 59
Oxprenolol (194), 249
Oxygen permeability (204), 53

P450 (208), 1
Paclitaxel-loaded solid lipid nanospheres (210), 61
PAGE (195), 147
PAMAM G4 dendrimer (197), 239
p-Aminophenyl-mannopyranoside (PAM) (210), 1
Parabens (195), 71
Paracetamol (208), 87, 101
Parkinson's disease (202), 125
Partial charge (197), 203
Partial solubility parameters (194), 117
Particles (199), 179
Particle size (193), 247; (196), 215; (203), 81; (204), 69; (206), 75; (208), 49; (210), 83
Partition (193), 97; (200), 121
Partition coefficient (195), 25; (200), 217; (205), 117
Patients (193), 227
PCS (196), 207
Pectin (197), 169, 181; (209), 79
Pectin/HPMC tablets (204), 127
Pectinolytic enzymes (197), 169
Peel testing (199), 29
PEG (200), 27
Pelanserin (201), 165
Pellets (199), 129, 187; (206), 13
Penetration (204), 97
Penetration enhancer (193), 49; (199), 119
PEO-PPO-PEO block copolymers (194), 103; (211), 37
Peptide (195), 35; (196), 173; (199), 17; (200), 181
Peptide cleavage (203), 115
Peptide degradation (195), 93
Peptide DNA condensates (203), 81
Peptide drugs (204), 137
Peptide nucleic acid (PNA) (196), 147
Peptidomimetics agents (210), 15, 29
Percolation threshold (204), 23
Percutaneous absorption (193), 213; (197), 77; (199), 1; (210), 69
Percutaneous absorption enhancer (198), 191
Percutaneous enhancers (203), 245
Percutaneous permeation (194), 249
Perfusion of rat jejunum segments (195), 147
Periodontal pocket (194), 103
Peritoneal macrophages (196), 235
Permeability (200), 41; (201), 131; (208), 35
Permeability alterations (207), 39
Permeability enhancement (195), 35; (207), 21
Permeability enhancer (194), 155; (197), 13
Permeability screen (210), 15
Permeation enhancement (204), 137
Peroral peptide application (194), 1
p-Glycoprotein (193), 157
pH (197), 87; (198), 139; (204), 53

Phagocytosis (195), 17
Pharmaceutical cream (203), 127
Pharmaceutical powders (202), 141
Pharmaceutical salt form (198), 239
Pharmacokinetic model (202), 89
Pharmacokinetics (193), 261; (194), 221; (197), 129, 213; (198), 83; (199), 159; (201), 59, 131; (202), 29, 97; (203), 61; (204), 17; (209), 37, 87
Pharmacopeial method (195), 159
Phase diagram (196), 141; (197), 35
Phase transition (201), 7
pH effect (197), 77; (201), 165
pH gradient (198), 213
pH monitoring alfurax (209), 79
Phosphatidylcholine (200), 73
Phosphatidylcholine liposomes (196), 215; (207), 39
Phospholipid (196), 135; (204), 69
Phospholipid–protein complex (194), 21
Phosphorus release (197), 53
Photooxidative damage (199), 39
Photostability (199), 49
pH partition (200), 243
pH-partition hypothesis (210), 69
pH-profile (198), 39
pH-responsive (207), 65
pH sensitive (203), 149
pH-sensitive complexes (194), 51
pH-sensitive release system (202), 103
Physical–mechanical properties (202), 63
Physical parameters (196), 131
Physical properties (194), 229
Physical stability (199), 151, 167
Physicochemical (193), 261
Physicochemical characterization (203), 255
Pig Peyer's patch (201), 15
Pilocarpine hydrochloride (198), 29
Pilocarpine ion-pair (202), 161
Piroxicam (193), 213, 261
Placenta (195), 115
PLA microspheres (196), 1
PLA–PEG (199), 95
Plasma (196), 11; (204), 17
Plasma renin activity (209), 87
Plasmid DNA (197), 221
Plasticisation (204), 23
Platelet aggregation (193), 123
PLGA (203), 193
PLGA microspheres (201), 15
PLGA poly (D,L-lactic acid-co-glycolic acid) polymer (208), 71
Pluronic F 127 (198), 147
p-nitrophenol (211), 19
p-Nitrophenyl acetate (205), 93
Polar surface area (201), 239
Poloxamer (195), 1
Poloxamer 407 gel (193), 49, 213; (199), 85
Poly(acrylamide/maleic acid) (203), 149
Polyanhydrides (194), 51
Poly(ε-caprolactone) (196), 177; (200), 231, 231
Polycarbophil (194), 239
Polycationic peptide (197), 221
Polyclonal antibodies (195), 147
Poly(2-(dimethylamino) ethyl methacrylate) (211), 79
Polydispersity index (196), 155
Poly-DL-(2,5-dioxo-1,3-pyrrolidinediyl) (200), 59
Poly(DL-lactide-co-glycolide) (207), 99
Polyelectrolyte complex beads (201), 51
Polyethylene glycol (193), 97; (195); (200), 27, 231 (201), 37; (203), 81, 255; (204), 137
Polyethylene glycol 300 (205), 159
Polyethylene glycol 400 (205), 195
Polyethylene-glycolylation (198), 83
Polyethylene oxide (195), 229, (202), 63
Poly(isobutylcyanoacrylate) (193), 37
Polyisobutylene (204), 171
Poly[lactic-co-glycolic acid] (196), 177
Polylactide (196), 115, (200), 133
Poly(lactide-co-glycolide) (195), 103, (196), 115
Poly (lactide-co-glycolic acid) microspheres (195), 179
Poly(lactide-co-glycolide) film (202), 29
Poly lactide–glycolide copolymer (200), 115
Poly(L-lactic acid) (211), 1
Polylysine (210), 97
Polymer (197), 1
Polymer aqueous dispersions (197), 169
Polymer distribution (196), 223
Polymer-drug conjugate (200), 59
Polymeric bone cements (209), 15
Polymeric matrix (201), 29
Polymeric micelles (205), 165, (209), 1
Polymeric nanoparticle (211), 1
Polymeric vector (210), 97
Polymeric vesicles (200), 73

Polymers (199), 119; (200), 271
Poly(methylmethacrylate) (197), 161
Polymorph (193), 137, (206), 63
Polymorphism (194), 147; (197), 35; (198), 167; (201), 221; (204), 1
Poly[α,β-(*N*-2-hydroxyethyl-DL-aspartamide)] (200), 59
Poly(*N*-isopropylacrylamide) (211), 1
Polyornithine (210), 97
Polyoxyethylene (202), 103
Polyoxyethylene alkyl ethers (209), 109
Polyoxyethylene ether surfactants (198), 7
Polypeptide lipidization (204), 111
Polyphosphazenes (211), 57
Polyplexes (211), 79
Polysaccharide (203), 169
Polysorbate 80 (200), 217; (210), 109
Polystyrene microparticles (201), 187
Polyurethane (201), 29
Polyvinylpyrrolidone (202), 1; (208), 87, 101
Porcine (194), 155; (200), 261
Pore former (201), 29
Porosimetry (197), 107
Porosity (198), 51; (204), 23
Post-traumatic endophthalmitis (204), 91
Powder (210), 83
Precipitation (194), 261
Prediction (195), 81
Prednicarbate (196), 165
Prednisolone (202), 103
Preformulation studies (196), 27
Preservatives (207), 89
Press-coated tablet (204), 7
Pressure sensitive adhesive (196), 105
Prilocaine (194), 103; (211), 37
Primaquine (198), 213
Principal component analysis (197), 203
Process monitoring (205), 79
Prodrug (195), 13; (200), 181; (202), 11, 79
Proguanil hydrochloride (206), 55
Proliposome (203), 61
Prolonged release (193), 1
Propranolol (194), 249
Propranolol HCl (204), 171
Propylene glycol (201), 121; (204), 171
Propyphenazone (197), 95
Protamine (197), 221; (202), 11; (206), 97
Protein adsorption (196), 231, 245
Protein conjugate stability (204), 81
Protein conjugation (204), 81
Protein delivery (210), 117
Protein formulation (200), 1
Protein kinase C_β inhibitor (198), 239
Protein release (197), 53
Proteins (196), 173
Protein stability (194), 69; (205), 23
Proteolytic enzymes (204), 43
Proximity (196), 187
Pseudolatex (193), 147
Pulmonary deposition (196), 95; (199), 7
Pulsatile protein release (194), 51
Pulsed release (193), 57
Punch deformation (198), 113
PVC (210), 109
Pyridoxine (202), 113
Pyrimidine 2′-deoxynucleosides (200), 181
Pyrolytic decarboxylation (202), 71

QSAR (201), 239
Quality control (204), 1
Quantum–chemical calculations (207), 1
Quercetin (205), 135
Quil A (196), 135

Rabbit (204), 35
Rabbits (197), 69
Racemization kinetics (196), 21
Ram extrusion (204), 117
Ramosetron (193), 205
Rate (202), 141
Rats (194), 81, 181, 193, 221; (195), 197; (197), 129; (204), (201), 59; (202), 89, 101
Receptor-mediated gene delivery (202), 151
Reconstituted lipoprotein (194), 21
Reconstructed epidermis (203), 211
Rectal absorption (198), 147
Reduced-serum cell culture (200), 41
Relative bioavailability (200), 153
Relative humidity (202), 71; (209), 27
Relaxation (203), 71
Release assays (209), 15
Release behavior (210), 109
Release kinetics (193), 239
Release mechanism (193), 1; (201), 165
Release model (197), 161
Release profile (196), 75
Release rate (209), 69

Remote loading (203), 61
Repeated intranasal dosing (199), 65
RES evasion (202), 1
Residual moisture (203), 1
Resolution (196), 21
Respiratory epithelium (208), 1
Response surface methodology (193), 37
Retinoic acid (193), 189
Retinol (196), 131
Reverse micelles (196), 207
Reversible reactions (202), 47
Reynold's number (201), 199
Rheological study (193), 49
Rheology (196), 37, 227; (199), 29
Rheology of creams (197), 143
Riboflavin (208), 61
Ripening inhibitors (200), 249
Routes of diffusion (193), 27

S-adenosyl-L-methionine (194), 61
Salbutamol (195), 13; (208), 13
Salbutamol sulphate (200), 93; (208), 111
Salicylic acid (194), 169; (210), 69
Salmeterol xinafoate (200), 279
Salsalate (204), 133
^{35}S anti-rabbit IgG (195), 147
SAXS (196), 207
Scale up (205), 3
Scanning-electron-microscopy (193), 85
Scintigraphic imaging (195), 179
Scintigraphy (195), 63
Scintillation (196), 187
Self-assembly (205), 109
Self-emulsifying systems (194) 84; (200), 53; (211), 29
Self-setting calcium phosphate cement (206), 1
Sensation responses (195), 55
Serotonin receptor antagonist (193), 205
Sesame oil (193), 189
Sheep (205), 159
S(+)-ibuprofen (193), 73
Sigmoidal release (204), 53
Significance of differences in statistical tests (209), 95
Silica (196), 257
Silica gel microspheres (200), 223
Silica xerogel (195), 219
Silicified microcrystalline cellulose (200), 67
Silicone (198), 229; (199), 29
Silicone membrane (197), 77
Silicone surfactant (196), 37
Similarity factor (209), 57
Simplex algorithm (198), 39
Single dose (202), 97
Site-specific delivery system (202), 103
β-Sitosterol β-glucoside (Sit-G) (200), 17
Skeletal drug delivery (206), 1
Skin (197), 87, 233; (200), 195
Skin barrier function (203), 211
Skin delivery (196), 63; (204), 159
Skin metabolism (200), 127
Skin penetration (207), 31
Skin penetration enhancers (199), 1
Skin permeability (202), 133
Skin permeation (194), 125; (199), 39; (205), 117
Skin transport (200), 107
Small angle X-ray scattering (196), 207, 201.
Sodium benzoate (194), 117
Sodium bicarbonate (202), 71
Sodium carbonate (202), 71
Sodium carboxymethylcellulose (202), 21
Sodium chloride-catalyzed degradation (196), 85
Sodium cholate (207), 21
Sodium ibuprofen (194), 117
Sodium lauryl sulfate (197), 193
Sodium *N*-ole-1-oyltaurate (194), 61
Sodium salts (201), 71
Sodium taurocholate (207), 21
Sol-gel (195), 219
Solid dispersion (195), 1; (197), 117; (205), 65, (206), 13
Solid lipid nanoparticles (196), 165, 183, 201, 211, 219, 227; 241; (199), 167; (205), 15
Solid lipid nanospheres (205), 3
Solid-reversed-micellar-solution (196), 193
solid-state characterization (206), 63
Solubility (198), 239; (201), 131; (203), 81; (205), 195
Solubility enhancement (197), 239
Solubilization descriptors (200), 217
Soluble form (201), 187
Solution (195), 13
Solution calorimetry (207), 57
Solvent evaporation method (196), 1
Solvent-evaporation method (195), 179

Sorbitol (208), 111
Soybean derived glucoside (SG) (200), 17
Soybean husk (206), 85
Soybean phosphatidylcholine (193), 189
Spacers (200), 87
Span 20 (203), 245
Span®20 (202), 133
Spherical crystallization (197), 95
Spheronisation (204), 117
Splenocytes (207), 71
Spontaneously hypertensive rat (209), 87
Spray-congealing (197), 117
Spray drying (200), 223
Spray-drying (200), 133; (203), 159
Spray mist (199), 77
Spreading coefficient (207), 77
Stability (194), 39, 61; (196), 215; (197), 87; (198), 1, 39, 229; (199), 141; (203), 1, 141; (204), 61; (205), 53; (211), 51
Stability in plasma and urine (200), 187
Stabilization (197), 117
Stabilization with yellow colourants (199), 49
Starch acetate (199), 205
Star design (205), 3
Statistical design (199), 129
Statistical method (204), 61
Status epilepticus (199), 65
Stavudine (201), 221
Stearic acid (195), 137; (199), 141; (200), 153; (201), 211
Sterically stabilized (193), 157
Sterilization (211), 79
Stomach (208), 61
Storage modulus (197), 143
Stratum corneum lipids (203), 245
Strength (200), 67
Streptokinase (202), 11
Structural characterisation (194), 169
Structure (193), 189; (198), 167
Structure–activity relationships (207), 1; (210), 15, 29
Styrene (198), 71
Subacute histological evaluation (197), 53
Sublimation (195), 239
Sublingual drug delivery (204), 127
Submicron emulsion (202), 161
Submicron emulsion stability (200), 249
Substituted amylose (193), 167
Suitable amount (195), 81
Sulfamethoxazole (202), 47
Sulfhydryl group introduction (211), 67
2-Sulfinobenzoic acid (208), 23
2-Sulfobenzoic acid (208), 23
Supersaturation (193), 231; (198), 229
Suppositories (196), 193; (199), 159
Surface-active agents (195), 189
Surface characterisation (194), 91; (196), 197; (211), 67
Surface charge (205), 173
Surface chemistry (198), 201
Surface energy (193), 13; (209), 27
Surface free energy (207), 77
Surface hydrophobicity (196), 245
Surface modification (195), 1
Surface smoothness (200), 93
Surface tension (194), 69; (199), 29
Surfactant (201), 7
Surfactant-free nanoparticles (207), 99
Surfactant-irritated skin (195), 189
Surfactant partition coefficient (207), 39
Surfactants (197), 143; (207), 89
Survival (210), 51
Sustained-delivery (203), 89
Sustained release (193), 73; (194), 139; (203), 235; (204), 127; (208), 13, 81
Sustained-release effect (203), 141
Sustained release matrix (199), 195
Sustained release tablet (202), 173
Swelling (194), 169; (195), 29; (199), 77
Symmetry (194), 147
Synchrotron radiation (203), 127
Synergistic effect (194), 51
Synperonic (193), 37
Systemic bioavailability (205), 127

Tablet compression (199), 205
Tablet excipients (197), 107
Tablet (195), 63, 125
Tablet strength (203), 71; (204), 23
Tablet weight (193), 167
Tacrine (196), 105
Tarazepide (196), 161
Targeted delivery (207), 71
Targeting (199), 95
Target-sensitive (193), 157
Taste masking (195), 137; (201), 211

Taxane (200), 27
Taxol (200), 27
TEER (208), 1
Teflon (208), 61
Temperature of gelation (194), 103
Temporal relaxation (199), 205
Tenofovir disoproxil (205), 93
TEPA (196), 85; (200), 187
Terbinafine (203), 109
Terbinafine hydrochloride (203), 149
Terbutaline (199), 151
Terephthaloyl chloride (211), 19
Ternary mixtures (197), 41
Terpenes (198), 179
Testing (204), 61
Testosterone suppression (194), 181
Tetracaine (202), 121
Theophylline (197), 107; (205), 53, 147
Thermal analysis (206), 85
Thermodynamics (202), 41
Thermo-responsive (205), 165
Thermosensitivity (203), 89
Thickness shear mode sensors (195), 25
Thimerosal (208), 23
Thiomers (194), 239
Thiomersal (208), 23
ThioTEPA (200), 187
ThioTEPA-mercapturate (200), 187
Three-dimensional measurement (199), 7
Three-layer system (195), 229
Three-point beam-bending (209), 27
Timolol maleate (196), 207; (197), 69
Titration calorimetry (194), 21
Tolbutamide (202), 165
Topical drug delivery (194), 125
Topical lotion (199), 49
Topical preparation (199), 119
Toremifene citrate (195), 219; (200), 223
Transcutol® (195), 171
Transdermal (193), 261; (196), 105; (197), 69; (200), 107
Transdermal delivery (194), 201; (195), 55; (207), 31
Transdermal drug delivery (193), 57 (209), 109
Transdermal Therapeutic System (199), 29; (200), 121; (204), 171
Transdermal transport (202), 121
Transepidermal water loss (200), 195
Transfection (208), 41; (211), 79
Transformation (193), 137
Transformations (194), 147
Transit time (204), 47
Transport (194), 209; (208), 1
Transport number (201), 121
Trauma (204), 97
TR146 cell culture model (194), 155; (200), 261
Tretinoin (199), 49
Triamcinolone acetonide (209), 37
Triboelectrification (195), 7
Triggered release (202), 11
Tripolyphosphate (201), 51
Trophoblast (195), 115
Tube reservoir (193), 57
Tween®20 (202), 133
Two-dimensional electrophoresis (196), 231, 245

Ultrasound (205), 23
Unloading (198), 113
Unsaturated fatty acid (201), 175
Uptake mechanisms (210), 15
Uranyl nitrate (194), 221
Urine (196), 11
UV sensing device (202), 113
UV-Vis (200), 279

Vaccine (196), 135; (200), 133
Validation PMMA (209), 15
Valproic acid (195), 115
Variability (193), 227
Vasopressin (197), 87
Vehicle effect (196), 105
Verapamil (200), 17
Vesicle (201), 7
Vesicles-ultradeformable (196), 63
Vesicular structure (204), 159
Vinblastine (200), 27
Viscoelasticity (196), 227; (209), 45
Viscosity (196), 37
Vitamin E (200), 53
Vitamin E TPGS (202), 63
Volatile anesthetics (202), 41
Volunteers (196), 11

Walker plot (193), 63
Water (195), 81

Water absorption (202), 141
Water solubility (205), 53
Water-soluble anionic dye (198), 97
Water-soluble drug (196), 75
Water sorption (207), 49
Wax (196), 219
WAXS (196), 219
Wet granulation (195), 81
Whey proteins (205), 147
Whisker growth (203), 203
w/o Concentrated emulsions (207), 7
w/o emulsion (193), 1
w/o/o double emulsion solvent diffusion method (196), 75
Xanthan gum (193), 73; (203), 179
Xanthan gum matrix (201), 109
X-ray crystallography (204), 133
X-ray crystal structure (194), 147
X-ray diffraction (198), 167; (203), 127
X-ray diffraction patterns (195), 45
X-ray photoelectron spectroscopy (198), 201
X-ray powder diffraction (208), 87

Yeast (204), 53
Young's modulus (209), 27

Zeta potential (193), 37